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  Over the last few decades, liposomes have generated a lot of interest as drug delivery 
vehicles to address the need for providing both increased therapeutic efficacy and decreased 
systemic exposure, simultaneously.  The challenge of increasing drug accumulation at diseased 
sites, without compromising the integrity and stability of the liposomal carrier during circulation, 
has been met with two possible solutions: (1) active targeting and (2) active triggering.  To 
achieve selective and site-specific delivery of drugs to tumors, active triggering methods have 
been developed wherein a responsive element is incorporated into the liposomal bilayer, which 
causes destabilization of the liposome upon exposure to the proper stimulus.  Endogenous stimuli 
can offer high specificities and sensitivities, if appropriate trigger groups exist so as to take full 
advantage of diseased site characteristics. 
  The research described herein involved the synthesis of redox-active, quinone-lipid 
conjugates that were prepared into liposomes for the containment and subsequent  
triggered release of encapsulated cargo.  Development of said system required (1) the synthesis 
and then characterization of various simple quinones and quinone propionic acids by cyclic  
voltammetry and X-ray crystallography and (2) the preparation of substituted 
quinone-dioleoylphosphatidylethanolamine lipids into liposomes and evaluation of their 
triggered release behaviors by fluorescence emission spectrometry.  
  Elucidation of the electrochemical properties of simple quinones and quinone propionic 
acids revealed a correlation between quinone substitution and reduction potential, meaning that 
the electronics of the quinone trigger can be adjusted through their chemical structure.  X-ray 
crystallography showed a highly distorted quinone ring proximal to the trimethyl-locked 
propionic acid side chain. 
xvi 
 
  Upon introduction of a chemical reducing agent, the four different substituted  
quinone-dioleoylphosphatidylethanolamine liposomes each displayed distinctive release 
behaviors, as indicated by the time-dependent increase in fluorescence signal as encapsulated 
calcein was released below its self-quenching concentration.  The individual release profiles 
demonstrate the influence of quinone substitution on the triggered response of these redox-active 
liposomes; thus, realizing the programmed delivery of liposomal contents through active 
triggering.  The information learned from this research project provides a solid foundation for 
exploring the triggered release of these redox-active liposomes by NAD(P)H:quinone acceptor 






1.1 Research Goals and Aims 
 The goal of this research is the development of redox-active liposome delivery agents 
with highly controllable stimuli-responsive behavior.  In particular, liposomes composed of a 
fusogenic phospholipid, dioleoylphosphatidylethanolamine (DOPE), covalently coupled to a 
functionalized, electrochemically active quinone (Q) stabilizer/trigger moiety are to be prepared 
to achieve a delivery system that can encapsulate and then selectively/specifically release its 
contents upon interaction with a stimulus (reducing agent or reductase enzyme). 
 The ability to contain, transport, and selectively deliver cargo at a given location or time 
is of paramount importance to a variety of applications, such as microfluidics, assays, diagnostics 
and sensors, separation techniques, and drug delivery, where micro- to nano-scale control and 
manipulation is the name of the game.  As a result, a variety of different delivery systems (e.g. 
micelles, polymeric micelles, dendrimers, polymer-drug conjugates, liposomes) have been 
designed in an attempt to meet this demand.  Liposomes have especially generated a lot of 
interest as drug delivery vehicles to address the need for attaining both increased therapeutic 
efficacy and decreased systemic exposure, simultaneously.   
 Liposomes offer several advantages as drug delivery containers due to their  
versatility—which is mainly a result of their amphiphilicity, general size (µm to nm), and 
molecular framework.  The hydrophobicity of many active pharmaceutical ingredients (APIs) 
makes their administration in the human body difficult to impossible without the aid of a 
solubilizing agent.  The lipophilic environment of the liposomal bilayer provides adequate seat 
for hydrophobic APIs during their transport (e.g. AmBisome), while the internal aqueous core 
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can accommodate more hydrophilic guests (e.g. Doxil, DaunoXome).  Moreover, the micro- to 
nanometer size of liposomes also makes possible the containment of APIs with a wide range of 
sizes and at variable doses (amount of encapsulated cargo).  The wide variety of lipids, lipid 
stabilizer/trigger groups, targeting moieties (e.g. peptides, antibodies), and non-immunogenic 
agents (e.g. poly(ethylene glycol) a.k.a. PEG, chitosan) that can constitute a liposome’s 
molecular framework makes possible highly specific, stimulus-actuated delivery of contents at a 
desired place or time.1  However, the full potential of liposomes is still being realized as more 
information about the microenvironment and differentiating characteristics (from healthy tissue) 
of tumors is being discovered.   
 The evolution of liposomes as drug delivery vehicles can be seen in the marketplace, as 
there have been 11 liposomal drug formulations approved for clinical use in the past 15 years, 
with 6 more currently in clinical development.2  In 1995, the first liposomal drug packaging was 
approved by the U.S. Food and Drug Administration (FDA); Doxil, a PEG-protected excipient 
for doxorubicin (chemotherapeutic), was marketed for the treatment of HIV-related Kaposi’s 
sarcoma and has also been approved in the last decade to treat metastatic breast and ovarian 
cancer.2  Composed of cholesterol (for added bilayer stability) and a mixture of hydrogenated 
soy phosphatidylcholine and PEGylated phosphoethanolamine lipids, Doxil has dramatically 
increased the drug survival time (circulation half-life)  and the drug concentration at the diseased 
site, resulting in it being six times more effective than free doxorubicin.3   
 The other currently marketed liposomal drug formulations (e.g. AmBisome, 
DaunoXome, and DepoCyt) and Doxil deliver their payloads by passive diffusion or non-specific 
degradation of the lipid bilayer.  Basically, the drug-loaded liposomes circulate in the 
bloodstream until they eventually accumulate at the diseased site via the enhanced permeation 
and retention (EPR) effect.4-7  In the interim during circulation, the non-specific means by which 
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the bilayer destabilizes and breaks down causes some of the free drug and lipids to leak out into 
normal, healthy tissue; this leads to harmful side effects (i.e. mucositis, hand-foot syndrome).  
While liposome-based transport of cytotoxic APIs does significantly improve the 
tumor-to-normal tissue drug ratio and lowers systemic exposure versus the free drug, this passive 
release mechanism still leaves something to be desired.  Ideally, the liposomal bilayer should be 
stable enough so that its cargo is well protected from the environment (and vice versa), but then 
destabilize only once the target site is reached.  Seemingly a dichotomy, the price for developing 
highly stable liposomes is often a decrease in the rate and/or amount of APIs released at the 
desired location, thus reducing medicinal efficacy.   
 In response, liposome drug delivery research has begun to navigate two general routes 
that address the need for increased drug accumulation without compromising the integrity and 
stability of the liposomal carriers: (1) active targeting and (2) active triggering.3  Nearly all 
nanoparticle-based therapeutics use the EPR effect as a guiding principle; therefore, active 
targeting cannot be separated from passive targeting (i.e. the EPR effect), because active 
targeting occurs after passive accumulation has already happened.5  Owing to this caveat, active 
triggering and the various approaches thereof will be discussed, and it is a major component of 
the goal of the research presented in this dissertation. 
 Programmed delivery of liposomal contents is typically achieved by having a triggerable 
functionality in the molecular design of the bilayer, that upon application of the proper “trigger” 
stimulus, either perturbs the permeability of the bilayer or completely disrupts its stability.8  
Stimuli that trigger liposomal contents delivery are grouped into two general categories: 
exogenous and endogenous triggers.8  External (exogenous) stimuli include radiation and 
temperature, which inherently require localization of the target area prior to treatment, thus 
preventing their use in cases where the diseased site is not necessarily known (e.g. early-stage 
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and metastatic cancers).8  In addition, liposome systems that utilize internal (endogenous) stimuli 
(i.e. pH and enzymes) to trigger the release of their cargo are more attractive for drug delivery, 
because they offer local control over payload delivery.  By making use of certain over-expressed 
or differentiating characteristics of a disease as an internal stimulus, these liposomal systems can 
be programmed to intrinsically trigger upon interacting with that stimulus, thus achieving site-
specific drug delivery.   
 Liposomes that are pH-sensitive take advantage of the increasingly acidic environment of 
cancerous tumors as the tumor interior is penetrated.  The extravasation of these liposomes, 
especially those with targeting ligands attached to their periphery, can lead to liposome 
internalization into cancerous cells via endocytosis where the endosomal/lysosomal pH is around 
5 or below, much lower than physiological pH 7.4.8  Therefore, the design of pH-triggered 
liposomes has primarily utilized fusogenic lipids so that escape from the endosomes is possible, 
which enables drug delivery directly into the cytoplasm and prevents the inevitable lysosomal 
degradation of the drug-loaded liposomes.  Fusogenic lipids undergo a phase transition, from a 
lamellar bilayer (Lα) to type II inverted hexagonal (Hα or HII) micelles, that results in 
destabilization of the liposome and delivery of its contents.8  Consequently, fusogenic lipids (e.g. 
phosphatidylethanolamines) have become a benchmark in the design of pH-sensitive liposomal 
formulations, which also include any combination of stabilizing lipids, polymers, amphiphilic 
molecules, and/or targeting ligands (e.g. antibodies, peptides).  The evolution of pH-sensitive 
liposomes has lead to highly complex, multifunctional systems whose behavior has not yet been 
well characterized, especially in vivo.3 
 The development of enzymatically-triggered liposome delivery agents has evolved 
naturally from the already abundant literature on enzyme-actuated prodrugs and bioactivable 
drugs.9    Currently, this young field of enzyme-activated liposome opening is based on a small 
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number of enzymes compared to the extensive library of enzymes used to activate prodrugs.  
Most of the literature surrounding enzyme-responsive liposomes is based on use of 
phospholipase A2 (PLA2) and matrix metalloproteinase (MMP) to trigger liposome opening;1,10-16 
however, a few other enzymes have also been explored: elastase,17 phospholipase C,18 and 
alkaline phosphatase.19  By exploiting enzymes that are intrinsically over-expressed in tumors, 
this drug delivery method has the potential to selectively and site-specifically dispense its 
liposome-encased chemotherapeutic cargo at cancerous regions in the body.  As Andresen et al. 
discuss in a recent review of this topic, a very interesting aspect of enzyme-triggered, PEGylated 
liposome systems is that enzymes seem to be capable of penetrating the protective PEG polymer 
sheath.1  Reports utilizing PLA2 (14 kDa) and MMP (72–92 kDa) approaches show that these 
enzymes can apparently reach and hydrolyze the lipids or peptides buried below the PEG sheath 
layer, which is quite a serendipitous outcome in order for this strategy to be successful.1,20-23   
By extension, the medium-sized enzyme that our liposome delivery system is  
targeting—NAD(P)H:quinone acceptor oxidoreductase type 1 (NQO1, 62 kDa)—should also be 
able of penetrating PEG coronas.  Human NQO1 is a reductase that is structurally suited for 
quinone-type substrates and is also upregulated in tumors.24-25  By taking advantage of its 
inherent structural specificity for quinones, hNQO1 can be further tuned to our 
quinone-functionalized liposomes by adjusting the electronics of the quinone molecule so as to 
obtain optimum enzyme-substrate interaction, leading to controlled liposome contents delivery. 
 The first aim of this research is the creation of a family of tunable, redox-responsive 
quinone-dioleoylphosphatidylethanolamine (Q-DOPE) lipids.  An important intermediate in the 
synthetic pathway to the target Q-DOPE lipids is a water-soluble compound, quinone-propionic 
acid (Q-COOH), which allowed the investigation of its electrochemical properties by cyclic 
voltammetry (CV) in aqueous media.  Structurally similar, simple quinones (those with no side 
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chain), and others deemed relevant, were also synthesized or purchased in order to see the effect 
of the propionic acid side chain on the electrochemical properties and also to (hopefully) support 
the trend(s) observed for the Q-COOH series.  The reduction potentials of the “model” 
Q-COOHs should equal that of the corresponding Q-DOPE lipids, because any functional 
changes to the end of the side chain are too far away from the quinone ring to have any 
substantial electronic influences.   
 Understanding how the various quinone substituents affect the electronics of each 
molecule is important in the development of our redox-triggered Q-DOPE liposomes, whose 
activation and rate of destabilization (payload delivery) is dependent on the electronic structure 
of the quinone moiety.  X-ray crystallographic analysis of all applicable (crystalline) Q-COOHs 
was conducted to investigate any structural variables (i.e. quinone substituents and trimethyl 
lock) that could influence their electrochemical behavior.  A decrease in quinone ring planarity 
due to ring strain26-38 leads to localization of the quinone π-system, and this change in electron 
distribution should be reflected in the electrochemical data (more negative reduction potentials).  
The information learned about the electronics and structure of these Q-DOPE lipid precursors is 
important in designing our triggerable liposome delivery system in order to exert molecular 
control over its activation and destabilization behavior.   
 Furthermore, enzyme-substrate reactivity and specificity can be optimized according to 
these electrochemical trends; the catabolism of the Q-COOHs by hNQO1 using enzyme kinetics 
assays has been studied by a colleague in our research group using quinone substrates that were 
chosen based on their reduction potentials.  Through careful selection of the substituted quinone 
moiety, in conjunction with its inherent structural reactivity and specificity for hNQO1, our 
tunable liposomes can also be targeted towards hNQO1 to minimize cross-reactivity with other 
enzymes or potential adventitious reducing agents in the body.  Based on the results from the 
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CV, X-ray crystallography, and enzyme assay experiments, 4 different Q-DOPE lipids were 
synthesized: QBr–DOPE (6c), QH–DOPE (6a), QMe–DOPE (6b), and QnPrNH–DOPE (6d).  
 The second aim of this research is examination of the encapsulation and triggered release 
behavior of the 4 selected Q-DOPE liposomes using fluorescence spectroscopy.  The various 
Q-DOPE liposomes were prepared according to the “lipid thin-film and extrusion” method.39-41  
To investigate the hosting and release properties of the various Q-DOPE liposomes, calcein (a 
fluorescent dye) was loaded into the liposomes above its self-quenching concentration (Cquench), 
and then gel-filtration chromatography was used to separate and remove the non-encapsulated 
calcein from the loaded liposomes.  Sodium dithionite (a powerful reducing agent) was added to 
initiate the destabilization of the liposomes by reduction of the quinone to the hydroquinone, 
followed by spontaneous intramolecular cyclization and elimination of the lactone, resulting in 
fusogenic (unstable) peripheral regions of the liposomes.  After contact-driven rupture of these 
fusogenic liposomes, the encapsulated calcein was released at a concentration below its Cquench, 
and the increase in fluorescence signal was monitored using emission spectroscopy.  To establish 
what qualifies as 100% release, Triton X-100 (a detergent) was added to completely and 
non-specifically disrupt the liposomal bilayer.  The average sizes and zeta potentials of these 
Q-DOPE liposomes were also measured in order to provide information that may help explain 
the results/observed trends from the fluorescence experiments.  The QnPrNH-DOPE liposomes 
were of particular interest, due to the possibility of the n-propylamino group being protonated, 
which would have a considerable impact on the overall charge of the bilayer. 
 The utility of these redox-responsive liposome delivery agents ranges from their use in 
drug delivery to achieve selective, site-specific transport of chemotherapeutics and/or imaging 




1.2 Importance of “Smart” Nanosized Delivery Systems 
1.2.1 Applications 
 The ability to contain, transport, and selectively deliver cargo at a given location or time 
is of paramount importance to a variety of applications such as microfluidics, assays, diagnostics 
and sensors, separation techniques, and drug delivery, where micro- to nano-scale control and 
manipulation is a key element to their success.  By 2015, the U.S. National Science Foundation 
projects that the nanotechnology market will be worth U.S. $1 trillion.5   
 One of the major obstacles involved in the employment of microfluidic devices is the 
ability to achieve temporal and spatial delivery and sufficient mixing of reagents within the 
channels of said devices.  To address this issue, Vreeland and Locascio used thermally-triggered 
liposomes to selectively deliver reagents in a microfluidic device, resulting in highly efficient 
mixing with an average time of 110 ms.42  Microfluidics also benefit from the use of 
nanocontainers to attain signal amplification, which is especially pertinent when their channels 
host (bio/immuno)assays and (bio/immuno)sensors.  Genç et al. developed an amperometric 
immunosensor that employed thermosensitive liposomes for the ultrasensitive detection of a 
cancer biomarker.43  The detection limit was lowered by two orders of magnitude, compared to 
that of the traditional immunosensor, and up to 11-fold amplification in signals was achieved as 
well.43  Similarly, other reports have utilized liposomes for signal enhancement in various 
assays44-47 and sensors.47-48  Particularly with cancer diagnosis, nanotechnology affords the 
possibility to realize rapid, more sensitive and selective detection of cancer biomarkers with 
high-throughput systems.48   
 In cancer diagnostics, magnetic resonance imaging (MRI) is one of the most common 
technologies used; however, it typically cannot detect entities with dimensions smaller than a 
few centimeters.48  To improve the sensitivity and limit of detection (LOD) of MRI, dendrimers 
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have been investigated as advanced contrast agents for highlighting cancerous tissue in the MR 
images.48  Majoros and coworkers have recently reviewed various dendrimer systems being 
explored for improving cancer diagnostics and therapy.49   
 Even separations and extractions benefit from the use of nanocontainers to enhance 
selectivity, sensitivity, and lower detection limits.  Micellar electrokinetic chromatography 
(MEKC) is used in capillary electrophoresis (CE) to lower the limit of detection and enhance 
sensitivity by separating (electrically neutral) analytes that partition into micelles 
(pseudo-stationary phase) from the aqueous mobile phase.50  Other micelle-based 
preconcentration techniques are used, such as analyte focusing by micelle collapse (AFMC) in 
CE,51 cloud point extractions,52-53 and micellar-enhanced ultrafiltration (MEUF).52  The latter 
two techniques have been used to separate and preconcentrate metal ions,52 and cloud point 
extraction has also been applied to isolate biological analytes (e.g. proteins, enzymes) for 
purification and to extract and preconcentrate environmental analytes (e.g. polychlorinated 
dibenzo-p-dioxins, polycyclic aromatic hydrocarbons, pesticides).53  While nanocontainers have 
significantly improved the analytical techniques discussed here, their application in the realm of 
drug delivery is where much of the current research lies. 
 The disease that most desperately needs selective, site-specific drug delivery is cancer, 
which is a leading cause of death around the world.  Between 2005 and 2015, the World Health 
Organization estimates that 84 million people will die of cancer and that deaths from cancer are 
expected to rise to over 11 million in 2030, worldwide.5,54  A multifactorial disease, cancer arises 
from genetic mutations that control division, proliferation, differentiation, and cell death that 
disrupt normal cell metabolism and tissue homeostasis.55  These gene mutations result from 
genetic defects and/or bodily exposure to environmental, mutagenic agents (e.g. tobacco, 
alcohol, radiation).48  At the early onset of cancer, normal cells undergo a progressive series of 
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abnormalities at the cellular level that lead to uncontrolled and continuous proliferation of cancer 
cells, which results in tumor formation and can also lead to metastases.55  The two major origins 
of cancer are activation of oncogenes and deactivation of tumor suppressor genes (TSGs).  
Oncogenes are responsible for regulating cell growth, proliferation, and/or differentiation, and so 
over-activity of oncogenes leads to excessive cell growth and division, leading to tumor 
masses.48  Tumor suppressor genes police any “illegal” or unnecessary cell growth and 
development by slowing or stopping cell division, so any mutations to TSGs also result in tumor 
formation.48   
 Oncology is one of the primary branches of medicine utilizing drug targeting, and some 
of the various cancer therapies used with nanoparticles include chemotherapy, immunotherapy, 
radiotherapy, photodynamic therapy, and others.55  Perhaps the most well-known of these is 
chemotherapy, which in combination with nanoparticles, delivers cytotoxic agents to cancerous 
sites in the body.  Some of these cytotoxic APIs include doxorubicin, paclitaxel, 5-fluorouracyl, 
irinotecan, camptothecin, and methotrexate.55-57  Protection of these drugs from the physiological 
environment (and vice versa), until the target site is reached, is fundamental toward achieving 
both increased efficacy and low systemic exposure.   
 On that note, pharmacokinetics and pharmacodynamics play very important roles in 
nanoparticle-based drug delivery.  Pharmacokinetics is simply defined as the effects of the body 
on the drug, while pharmacodynamics is the effects of the drug on the body.  Upon intravenous 
injection, drugs go through adsorption, distribution, metabolism and elimination (ADME), and 
an optimum ADME process depends mostly on the properties of the drug (i.e. molecular weight, 
shape, charge, aqueous solubility).55  From a nanoparticulate-DDS perspective, both the 
pharmacokinetics and pharmacodynamics can be improved if the DDS is non-immunogenic 
(“invisible” to the body) and favorably alters the biopharmaceutic and pharmacokinetic 
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properties of the drug by allowing them to be delivered intravenously (in higher doses than the 
free drug) and site-specifically.55  In addition to the properties of the encapsulated drug, the 
pharmacological profile of liposomal drug formulations is also dependent upon the ADME of the 
liposome excipient, the drug release rates, and the total amount of drug released.57  Thus, the 
therapeutic efficacy of the encapsulated drugs mainly depends on the pharmacokinetics and 
tissue distribution of the nanoparticulate-DDS.55,57  Ideal delivery vehicle characteristics include 
the following: (1) protection of drug cargo from the environment (and vice versa),                    
(2) containment of a wide variety of drug molecules, (3) improvement of tumor-to-normal tissue 
drug ratios, (4) transportation/delivery of variable dose amounts, (5) controlled and site-specific 
delivery of contents, and (6) biocompatibility/biodegradability.5 
1.2.2 Types of Drug Delivery Systems (DDS) 
 Not surprisingly, a large majority of the research being done today in the field of 
nanotechnology is geared towards improving the selective and site-specific delivery of reagents, 
particularly those that will enhance the diagnostics, sensing, monitoring, and/or treatment of a 
disease.  Among these applications in the healthcare industry, the careful delivery of drugs to 
diseased sites is of particular interest, as is evidenced by the breadth and variety of drug delivery 
systems (DDS).  While a myriad of DDS are discussed in the literature, only a select few are 
delineated here. 
 Traditional micelles, or “surfactant micelles,” are characterized by an inner hydrophobic 
core that is defined by an outer hydrophilic corona.55,58  Surfactant molecules spontaneously 
assemble into micelles only above the critical micelle concentration (CMC), forming these 
aggregate structures of 5–100 nm in diameter.55  In the late 1960s, researchers began to 
investigate the use of micelles as drug carriers, because their properties can be easily modified 
(e.g. size, charge, surface properties) and are pharmacologically viable for distribution in the 
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body.55,58-59  Micelles possess many of the same advantages as liposomes, such as the ability to 
contain both hydrophilic and hydrophobic drugs, protection of encapsulated cargo, a degree of 
functionality/control, to name a few.  In fact, several micellar-based formulations are currently in 
clinical trials, including NK105 (paclitaxel, Phase II), NC-6004 (cisplatin, Phase I/II), and 
SP1049C (doxorubicin, Phase III).55  The two major disadvantages of micelles that limit their 
application as DDS are (1) their smaller size, that limits the amount of encapsulated cargo, and 
(2) their relative instability, especially in biological fluids, where the CMC decreases, resulting 
in premature leakage of the drugs.55  As a result, polymer-based micelles have gained much 
attention to fill the voids of these traditional micellar systems. 
 By comparison, polymeric micelles (PMs) have CMC values several orders of magnitude 
much lower than traditional micelles, making them much more stable and less susceptible 
towards dilution.58-62  For example, an aqueous solution of sodium dodecyl sulfate (surfactant) 
has a CMC of about 2300 mg L−1,63 versus a poly(saccharide) PM whose CMC is only about  
5 mg L−1,58 which amounts to nearly a 500-fold decrease.  Polymeric micelles are prepared from 
amphiphilic diblock, triblock, or even graft copolymers which form 10–100 nm aggregates 
(above the critical aggregation concentration, CAC) are composed of an inner hydrophobic core 
and an outer hydrophilic shell.58,60    Some common hydrophilic polymers used in PMs are 
poly(ethylene glycol), poly(N-vinyl-2-pyrrolidone), and poly(vinyl) alcohol, while the 
hydrophobic core most often consists of polyesters and poly(amino acids).62,64-65  PMs 
masquerade under various aliases in the literature: micelles, nanospheres, core-shell 
nanoparticles, micelle-like nanoparticles, nanocapsules, and polymersomes.61  PMs offer a 
degree of flexibility, compared to their low-molecular-weight counterparts, in that both the 
hydrophilic and hydrophobic polymers can be engineered so as to allow attachment of a wide 
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variety of drug molecules; furthermore, PMs can be made to actively target certain diseased sites 
by attaching targeting moieties onto their peripheral polymer chain ends.58,61 
 Dendrimers are monodisperse, highly-branched, three-dimensional structures composed 
of three distinctive architectural components: (1) an interior core onto which (2) “generation” 
layers of repeating molecular units are radially attached and then (3) terminated by some 
functionality that defines the exterior of the tree-like dendrimer.56,61,66  Most often composed of 
poly(amido amine) and poly(propylene imine), dendrimers range from 1–100 nm3 in size and 
become increasingly more rigid and globular as the generation is increased.56,61,66  For 
biomedical applications, fourth-generation dendrimers (and higher) are used and have found 
great applicability in drug delivery and as imaging agents,49 transporting bioactive cargo 
encapsulated in the interior layers or covalently bound to the surface of the dendrimer.56,61,66  
VivaGel (Starpharma) is a dendrimer formulation in clinical development as a topical 
microbicide to prevent the spread of certain sexually transmitted diseases.49,61  The architecture 
of dendrimers (e.g. size, shape, branching, functionalities) can be controlled to offer desired 
properties pertinent to a given application, much like PMs.56,66-67  However, the main drawback 
of dendrimers as DDS is the rapid and uncontrollable release of their encapsulated contents 
which has hindered their success in clinical trials.56 
 Polymer–drug conjugates are essentially macromolecular prodrugs that are composed of 
drug molecules that are covalently linked to a biocompatible, water-soluble polymer (between 
10,000–100,000 MW) through biodegradable bonds.61,68  Some examples of commonly used 
polymers are poly(ethylene glycol) a.k.a. PEG, N–(2–hydroxypropyl)methacrylamide or HPMA, 
and poly(lactide–co–glycolide) a.k.a PLGA.69  In aqueous environments, the polymer-drug 
conjugates assemble into a micelle-like state that have 5–100 nm dimensions.61,69  Examples of 
such therapeutics include polymer-drug and polymer-protein conjugates, and even PMs and 
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dendrimers that contain covalently bound drugs.  The most promising pharmaceutical candidates 
in clinical trials are the polymer–protein and polymer–anticancer drug conjugates; however, 
several formulations are currently undergoing clinical evaluation.68-69  One example of a quite 
successful polymer-drug conjugate in Phase III clinical trials is poly(L-glutamic acid)–paclitaxel 
(CT-2103, Xyotax).68  Polymer-drug conjugates can be actively targeted to tumors by 
incorporating ligands into their formulation.68-69  In the medical arena, polymer-drug conjugates 
are being used as new targeted anti-angiogenic therapies and as modulators of cellular apoptosis 
(i.e. single pro-apoptotic agents in cancer or anti-apoptotic agents in ischemia).61  Major 
drawbacks of these DDS are their limited cargo-carrying capacity and the fact that the drug, 
itself, is chemically modified through its covalent attachment to the polymer carrier, an alteration 
that can affect its efficacy and mechanism of action compared to the free drug.69 
 As more information is learned about the physiology of certain diseases (most notably, 
cancer) and great strides are made in the advancement of nanotechnologies, researchers are 
beginning to better identify and engineer critical components in drug delivery systems.  As the 
search for a “magic bullet” continues, a few drug delivery vehicles seem to be within in reach of 
attaining this elusive status.  Liposomes, in particular, are a paradigm in the realm of smart drug 
delivery systems and have been speculated as a potential frontrunner for providing all-inclusive 
drug delivery.70 
1.3 Liposomes, the “Quintessential” DDS? 
1.3.1 Advantages 
 Especially in the last 30 years, liposomes have generated a lot of interest as drug delivery 
vehicles to address the need for providing both increased therapeutic efficacy and decreased 
systemic exposure, simultaneously.  They were the first nanoparticle-based DDS to reach the 
market and have one general advantage over other types of DDSs: with respect to drug delivery, 
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the knowledge about how to encapsulate drugs into liposomes and their stability and toxicity is 
substantially higher in this field.71  Liposomes offer several advantages as drug delivery 
containers due to their versatility, which is mainly a result of their amphiphilicity, general size 
(µm to nm), and molecular framework.   
 The hydrophobicity of many APIs makes their administration in the human body difficult 
to impossible without the aid of a solubilizing agent.  The lipophilic environment of the 
liposomal bilayer provides adequate seat for hydrophobic APIs during their transport (e.g. 
AmBisome), while the internal aqueous core can accommodate hydrophilic guests (e.g. Doxil, 
DaunoXome).  Compared to drug-conjugates and other nanoparticles that contain covalent 
attachments of drug molecules, liposomes undergo less rigorous standardization because the 
actual drug is unmodified and merely carried within the liposome itself.  Moreover, highly 
cytotoxic drugs are contained and shielded from the environment, thereby lowering systemic 
exposure and increasing/maintaining the therapeutic index of the drug by preventing its 
degradation by the body.  Larger doses of the APIs can be administered as well because of the 
protection afforded by the liposome from the body during circulation.  The micro- to nanometer 
size of liposomes makes possible the containment of APIs with a wide range of sizes and at 
variable doses (amount of encapsulated cargo).   
 In the majority of the cases, their size also allows them to reach both localized and 
systemic sites, because liposomes fall into the optimum size range of 50–150 nm to exploit the 
enhanced permeation and retention (EPR) effect but avoid extravasation into healthy tissues.72  
The wide variety of lipids, lipid stabilizer/trigger groups, targeting moieties (e.g. peptides, 
antibodies), and non-immunogenic agents (e.g. poly(ethylene) glycol (PEG), chitosan) that can 
constitute a liposome’s molecular framework makes possible highly specific, stimulus-actuated 
delivery of contents at a desired place or time.1   
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 The special storage and handling of liposomes, because of their short shelf life, is one 
disadvantage of using them as DDSs.  In aqueous solution, hydrolysis and oxidation of the 
phospholipid chains can occur, leading to degradation of the liposome.47  Other factors, such as 
the chemical composition of the membrane, the nature of the entrapped cargo, and the pH and 
temperature of the storage solution impact the stability of liposomes.47  To this end, liposomes 
are normally stored at 4 °C under an inert gas.47   
 Despite these few drawbacks, the full potential of liposomes is still being realized as 
more information about the tumor microenvironment is being discovered.  The versatility of 
liposomes, coupled with the differentiating characteristics of tumors, has led to a growing 
number of liposomal formulations in the marketplace and in clinical trials, suggesting that 
liposomes have yet to reach their full potential. 
1.3.2 1st– and 2nd–Generation Liposomes 
 Liposomes were first recognized by Bangham and co-workers73 in 1965, even though 
lipid researchers in the mid-1800s were studying these colloidal structures, known at the time as 
lecithin emulsions, sols, and suspensions.74  However, these earlier researchers did not realize 
that the colloidal membranes formed by aqueous lecithin phases were self-closed and contained 
inner compartments, a characteristic that was later recognized and denoted as large multilamellar 
liposomes (or “Bangasomes”).74  The internal aqueous cores are separated from the surrounding 
bulk solution by lipid membranes.74  This first generation of liposomes are characterized as 
spherical particles composed of a phospholipid membrane(s) that can host both hydrophilic (in 
the aqueous interior) and hydrophobic (in the bilayer) guests, such as drug molecules.3  Much 
later in the late 1980s to early 1990s, liposomes as drug delivery systems suffered much criticism 
and doubt when in vivo studies of liposome-encapsulated formulations were unsuccessful, 
primarily due to their rapid uptake in the reticuloendothelial system (RES) and subsequent 
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elimination from the body.74  The RES, also known as the mononuclear phagocytic system 
(MPS), commands an arsenal of opsonin proteins (e.g. IgG antibodies, fibrinogen, complement 
protein C3b) that “mark” foreign particles to be phagocytosed by phagocytes and circulating 
monocytes in the liver, spleen, bone marrow, and lymphatic tissue, leading to elimination of 
these particles from the body.55,75-79   
 The solution to reduce the rapid clearance of liposomes from the body by the RES gave 
birth to the second generation of liposomes: sterically stabilized liposomes that contain a 
protective polymer coating on the periphery, are more adept at avoiding capture by the body’s 
immune system.3,6-7,78-81  The most popular polymer coating used to protect liposomes from the 
RES is poly(ethylene glycol) a.k.a. PEG, of at least 2,000 MW, and these modified liposomes are 
called PEGylated, PEG-protected, or Stealth liposomes.71,76-77  While the exact mechanism by 
which the PEG corona protects liposomes from opsonization is still not fully understood,75,77 two 
possible explanations have been posed: (1) PEG acts as a shield, sterically hindering the 
approach and adsorption of opsonin proteins to the liposome surface; and (2) Certain serum 
proteins adsorb to the liposome surface, possibly partly caused by the PEG corona, and act as 
nonspecific dysopsonins that fortuitously decrease the adsorption of opsonins.71,77,81  More 
information about protein adsorption to liposomes must be acquired in order to determine exactly 
how PEG protects liposomes, and other nanoparticles, from the RES.71  As a side note, Yoo et al. 
have reviewed some of the drawbacks of PEGylation and also discuss recent developments to 
increase the circulation of nanoparticles in the body.82 
  In general, as a result of PEGylation, these stealth liposomes have been shown to remain 
in circulation for increased periods of time compared to their first-generation counterparts, which 
allowed them to fully harness what is known as the enhanced permeability and retention (EPR) 
effect.  Longer circulation times are required in order for liposomes to reach and amass at 
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diseased sites (i.e. tumors, inflamed tissue) possessing certain structural abnormalities that are 
characteristic of the EPR effect.  Due to extensive angiogenesis and the chaotic nature of cancer, 
the environment of tumors is plagued by a high density of defective blood vessels that are dilated 
and disordered.4-6,75,83  This leaky vasculature (pore dia. ~100–2000 nm) is more permeable to 
macromolecules and molecular assemblies (e.g. liposomes), versus normal healthy vessels (pore 
dia. ~2–6 nm), leading to their preferential accumulation in tumor tissues.4  Additionally, 
inefficient lymphatic vessels increase the retention of these larger molecular entities within the 
tumor interstitium because of poor drainage.4-5  Thus, the optimum size so as to maximize the 
EPR effect for liposomal DDSs ranges between 10–150 nm in diameter to avoid leaking into 
healthy tissue and elimination by the kidneys (> 10 nm) and the liver (< 100 nm).5,72 
 Besides avoiding the RES and dodging healthy tissues, the ideal sizes of liposomes also 
provide another advantage to their use in drug delivery.  High tumor interstitial fluid pressure 
(IFP) is a potential barrier for some DDSs, particularly those that are smaller in size.  High IFP in 
tumors results from interstitial hypertension inside tumors due their poor lymphatic (drainage) 
system and vascular hyperpermeability.5,72  Movement of fluid is centralized at the core of solid 
tumors and flows outward toward the periphery, causing the IFP to be slightly higher as a 
function of depth in tumors.5,72  Drug-loaded nanocarriers, such as liposomes, are less affected 
by high IFP in tumors because their larger size can effectively fight against the opposing fluidic 
current.5,72 
 As a result of more stable in vivo formulations, 11 clinically-approved liposomal 
formulations have been developed in the past 15 years, with 6 others currently in clinical trials.2  
As a single therapeutic nanocarrier, liposomes have primarily been developed for cancer 
treatment.84  Doxil, Myocet, and DaunoXome are all currently-marketed liposomal formulations 
used in a variety of cancer therapies, while some others are still in clinical trials.84  The first 
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liposomal drug packaging approved by the FDA and the “go-to” example of a successful 
liposome-based DDS is Doxil.  Based on a PEGylated excipient for Doxorubicin, Doxil was 
initially approved and marketed for the treatment of HIV-related Kaposi’s sarcoma, and was 
approved (2001) and has been used to treat metastatic breast and recurrent ovarian cancer.  It is 
composed of cholesterol for added bilayer stability and a mixture of hydrogenated soy 
phosphatidylcholine and PEGylated phosphoethanolamine lipids. With its PEG protection from 
the RES, Doxil has dramatically increased the circulation half-life time and drug concentration at 
the diseased site via the EPR effect, amounting to it being six times more effective than free 
Doxorubicin.3   
 A pH gradient across the bilayer is used to load Doxorubicin into these liposomes, and 
this transmembrane pH gradient is hypothesized to become disrupted once Doxil liposomes 
reach the tumor site, releasing doxorubicin into the local area.71  There exists a delicate balance 
in terms of the stability of Doxil liposomes in circulation versus in the tumor, as the 
encapsulation/release of doxorubicin relies simply on a proton gradient.71  The passive release 
mechanism by which the currently-marketed liposomal formulations (e.g. Doxil, AmBisome, 
DaunoXome, DepoCyt, etc.) deliver their payload involves passive diffusion or non-specific 
degradation of the bilayer.  Due to this non-specificity of destabilization, some of the free drug is 
able to leak out into healthy tissue during circulation, leading to harmful side effects and 
decreased concentration of the drug at the diseased site.  While liposome-based transport of 
cytotoxic drugs does significantly improve the tumor-to-normal tissue drug ratio and lowers 
systemic exposure versus the free drug, this passive release mechanism still leaves something to 
be desired.   
 Ideally, the liposomal bilayer should be sufficiently stable so that its cargo is well 
protected from the environment (and vice versa) but then destabilize only when the target site is 
20 
 
reached.  Seemingly a dichotomy, the price for developing highly stable liposomes is often a 
decrease in the rate and/or amount of APIs released at the desired location, thus reducing 
medicinal efficacy.  In response, liposome drug delivery researchers have pioneered two general 
routes that address the need for increased drug accumulation without compromising the integrity 
and stability of the liposomal carriers: (1) active targeting and (2) active triggering.   
1.4 Stimuli-responsive Liposomes  
1.4.1 Active Targeting 
 Active targeting is one route employed to increase the site-specific delivery of drugs to 
tumors by facilitating both (1) direction to cancerous cells and (2) drug retention by preventing 
retrograde movement of the liposomes back into the bloodstream due to high interstitial fluid 
pressure (IFP).3  It involves utilizing certain over-expressed characteristics of tumors (e.g. 
integrin, folate and transferrin receptors) to enhance liposome accumulation in tumor tissue by 
incorporating targeting moieties onto the outside of the liposome, either on the bilayer surface or 
on the distal end of PEG chains.8,55  Identifying key markers of cancers, such as the folate 
receptor that is upregulated in a variety of tumors (e.g. ovary, lung, colon, brain, and breast), 
provides a discriminating factor for targeted liposomes to distinguish between diseased and 
healthy tissues.85  The binding of these targeting groups to cancerous cells also helps decrease 
the retreat of liposomes back into circulation due to high IFP.  Drug-loaded nanocarriers, such as 
liposomes, are less affected by high IFP in tumors compared to smaller DDSs because of their 
larger size.5,72   
 Nearly all nanoparticle-based therapeutics use the EPR effect as a guiding principle, 
except those systems that are targeted to angiogenesis receptors on endothelial cells that are 
over-expressed in tumors, thereby destroying the tumor microvasculature (e.g. integrin-αVβ3, 
negatively charged phospholipids).1  Therefore, active targeting truly cannot be separated from 
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passive targeting (i.e. the EPR effect), because it occurs after passive accumulation has already 
happened.5  Active targeting is mainly beneficial for cellular internalization, and moreover, can 
compromise the long circulation properties of the liposome when the targeting ligands are 
located on the periphery or if the ligands increase unspecific binding to non-target tissue.1,71  
Additionally, targeting ligands with high binding affinity may cause an effect known as the 
binding site barrier, which impedes further penetration of the liposomes deeper into the tumor.1,71  
The binding site barrier phenomenon occurs when targeted liposomes bind tightly to the first line 
of cells encountered after extravasation, an event that causes a blockage and a “pile-up,” much 
like a wreck on a highway.1  It has been suggested that control over the binding affinity of 
targeting moieties to the cell surface receptors may be required in order to prevent binding that is 
too strong, such that deeper extravasation of targeted liposomes can be achieved.1,72    
1.4.2 Active Triggering 
 Programmed delivery of liposomal contents is achieved by building a triggerable 
functionality into the molecular design of the bilayer, that upon application of the proper 
stimulus, either creates leaky interfacial membrane regions, increases the heterogeneity of the 
lipid membrane, or causes defects in the bilayer that allows the entrapped contents to be 
released.8  The extent of this destabilization can range from simple perturbation of the 
permeability of the bilayer or completely disrupting its stability.   
 Stimuli-responsive liposomal delivery systems can thus be grouped into two general 
categories: exogenously- and endogenously-triggered.8  External stimuli include radiation and 
temperature, which inherently require localization of the target area prior to treatment and 
therefore prevents their use in cases where the diseased site is not necessarily known (e.g. 
early-stage and metastatic cancers).8  In addition to this reason, liposome systems that utilize 
internal stimuli (i.e. pH and enzymes) to trigger the release of their cargo are more attractive to 
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drug delivery, because they offer local control over payload delivery.  By using a certain 
over-expressed or differentiating characteristic of a disease as an internal stimulus, these 
liposomal systems can be programmed to intrinsically trigger upon interacting with that stimulus, 
thus achieving site-specific drug delivery.   
1.4.2.1 Temperature  
 The application of heat, or mild hyperthermia, to trigger the release of encapsulated drug 
cargo from thermosensitive liposomes affords a unique type of combination therapy.  Mild 
hyperthermia, which is the local heating of tumor tissue slightly above body temperature (to 
~41–43 °C), is selectively detrimental to tumors and can increase the effectiveness of chemo and 
radiation therapy.86-87  Tumors are more susceptible to an increase in temperature and experience 
enhanced blood flow and vascular permeability versus healthy tissue, further augmenting the 
EPR effect.86-87  Mild hyperthermia also selectively interferes with some critical biological 
functions of cancer cells, as opposed to normal cells, such as DNA synthesis and repair.86-87  For 
these reasons, the coupling of mild hyperthermia with thermosensitive liposomes for drug 
delivery is synergistically advantageous and also works to cooperatively minimize damage to 
normal tissue. 
 Two different approaches can be used to trigger drug delivery from thermosensitive 
liposomes at tumor sites: (1) interstitial drug release and (2) intravascular drug release.87  
Interstitial drug release involves heating tumor tissue after liposome accumulation within the 
tumor interstitium has already happened so that the encapsulated drugs are rapidly released in 
close proximity to cancerous cells.  With intravascular drug release, mild hyperthermia is applied 
at the tumor site before the thermosensitive liposomes reach the tumor site; therefore, immediate 
drug release occurs upon their arrival in the tumor vasculature.87 
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 According to Sawant and Torchilin, thermosensitive liposomes can be grouped into two 
general categories: (1) those containing temperature-sensitive lipids and (2) those that 
incorporate temperature-responsive polymers onto their bilayer surface.3  In both systems, the 
thermosensitive liposomes become destabilized by the application of mild hyperthermia.   
 The main type of temperature-sensitive lipid used in thermosensitive liposomal 
formulations is 1,2–dipalmitoyl–sn–glycero–3–phosphocholine (DPPC), and 
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) is commonly added to adjust the main 
transition temperature.8,88  Temperature-sensitive lipids undergo a phase transition (gel to liquid) 
at a given temperature, called the Tm, which is between 43–45 °C for DPPC/DSPC systems.8,86  
When these lipids are formulated into liposomes and heated to their Tm, leaky interfacial regions 
or “defects” in the bilayer result and allow encapsulated cargo to be released.   
 Several variations of this DPPC/DSPC liposome system have been reviewed in the 
literature, with emphasis on those discussed by Gerasimov et al.89 and Andresen et al.8  Other 
bilayer components were added to impart desired characteristics to the thermosensitive 
liposomes, such as stability with cholesterol (Chol),90-92 longer circulation times with 
PEG2000-DSPE lipids,90,93-94 and general bilayer adjustments with phosphatidylcholine (PC),90,93 
and/or elaidic acid.89,95   
 Thermosensitive liposomes can also incorporate lysolipids, or pore-forming amphiphiles, 
into their bilayers that allow a lower (but still sharp) transition temperature to improve membrane 
permeability.8  Needham et al. developed a sterically stabilized liposome composed of 
DPPC/DSPE–PEG2000 and a lysophospholipid, 1-myristoyl-2-palmitoyl-sn-glycerol-3-
phosphocholine (MPPC).8,96-97  In fact, this type of formulation encapsulating the anticancer 
agent Doxorubicin (also known as ThermoDox) has reached Phase-III clinical trials for the 
treatment of primary liver cancer.86  Petrov and coworkers have also developed DPPC/DPPG 
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liposomes containing lysolipids derived from cholic acid, lysine, and spermine.98-99  Very 
recently, Genç et al. developed thermosensitive liposomes composed of DPPC/DPPE 
(1,2-dipalmitoylphosphoethanolamine) and lyso-palmitoylphosphatidylcholine (lyso-PPC) that 
were used for signal enhancing in an immunosensor, which exemplifies the range of applicability 
of these types of liposomes.43 
   The other genre of thermosensitive liposomes is that which has temperature-sensitive 
polymers, or LCST (lower critical solution temperature) polymers, integrated onto their surface.  
LCST polymers undergo a temperature-driven transition from a coil to a globular conformation 
in aqueous media: these polymers are more hydrophilic (coil) below the LCST and become more 
hydrophobic (globular) above the LCST.86  As a result, the bilayer experiences a measure of 
mechanical distortion that destabilizes the liposome and facilitates drug release.86  Polymer 
derivatives of N-isopropylacrylamide (pNIPAA) that contain hydrophobic moieties as anchors 
are used most often, and the LCST of pNIPAA is adjusted by copolymerization.86,100  For 
example, Hayashi and Kono copolymerized pNIPAA and octadecylacrylate to generate a 
thermally-sensitive copolymer that was incorporated into dioleoylphosphatidylethanolamine 
(DOPE) liposomes, which were stable below 30 °C but rapidly released their contents at  
40 °C.101  pNIPAA has also been copolymerized with propylacrylic acid, the latter of  
which is pH-responsive, thus resulting in a dual-responsive system.102  As an alternative to 
non-biodegradable pNIPAA, Paasonen et al. used poly(hydroxypropylmethacrylate) a.k.a. 
pHPMA.103  Another LCST polymer, poly(2-(2-ethoxy)ethoxyethyl vinyl ether-block-octadecyl 
vinyl ether) or EOEOVE-block-ODVE, has an LCST around 40 °C and has been incorporated 
into PEGylated liposomes by Kono and coworkers.104-105    
 A convenient segue into the following section about photosensitive liposomes is to 
briefly discuss photothermal triggering, a method that combines both heat and light stimuli for 
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liposome opening.  Photothermal triggering takes advantage of the heat emitted from 
light-absorbing chromophores during their decay from an excited state to the ground state.106  In 
other words, heat generated from irradiation by light is harnessed to effect bilayer destabilization 
in liposomes.  The key component in most photothermally-triggered liposomes is gold 
nanoparticles or hollow gold nanoshells, both of which are responsible for translating light 
absorption into a highly-localized hyperthermal effect.  Paasonen et al. have developed 
photosensitive liposomes composed of DPPC/DSPC with gold nanoparticles embedded in the 
bilayer.103,107  Similarly, Wu and coworkers used hollow gold nanoshells in their PEGylated, 
DPPC-based liposomes that are destabilized with 800-nm, near-infrared light.108 
1.4.2.2 Light 
 Using light as a stimulus for liposome opening is advantageous from the viewpoint that it 
offers a broad range of adjustable parameters (e.g. wavelength, intensity, duration) with which to 
tune the system.89,106  However, one of the limiting factors with this triggering method is that 
some wavelengths of light may not be suitable for drug delivery applications because of 
hazardous side effects from prolonged exposure and/or interfering chromophores present in the 
body.89  According to Wang et al., near-infrared light may be the optimum wavelength to use for 
phototriggering liposomal drug delivery systems.109  Nonetheless, several comprehensive 
reviews have been written over the years about photoactivated liposomes that destabilize as a 
result of light-induced polymerization, fragmentation, or isomerization.89,106,109 
 Photopolymerizable liposomes are composed of photosensitive lipids that form a 
cross-linked lipid network upon exposure to UV light; the crosslinking event creates defects in 
the bilayer and subsequent release of the carried cargo.109  The overwhelming majority of these 
systems contain 1,2-bis[10-(2’,4’-hexadienoyloxy)decanoyl]-sn-glycero-3-phosphocholine 
(bis-SorbPc), a photosensitive lipid that is the key player in the triggerable mechanism.8,109  For 
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example, Bondurant et al. developed photopolymerizable liposomes composed of 
PEG2000-DOPE/Chol/DOPC/bis-SorbPC, and later it was concluded that the permeability of 
these liposomes increased 28,000-fold upon UV exposure.110-112  Lamparski et al. determined 
that the rate of contents release depends on the extent of bis-SorbPC polymerization (and other 
factors) based on experiments with their DOPE/bis-SorbPC photosensitive liposomes.109  With 
the addition of a green light absorbing dye, distearoyl indocarbocyanine (DiIC), Mueller et al. 
were able to make their PEG2000-DOPE/bis-SorbPC/DOPC liposomes sensitive to  
both UV and visible light.109,113  More recently, a diacetylenic phospholipid called 
1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC)  was incorporated into 
DPPC liposomes to induce rupture when irradiated with 254-nm light.114  This new 
photopolymerizable component, DC8,9PC, was also included in the formulation of 
PEG2000-DSPE liposomes.115 
 Photofragmentation, or photodeprotection, involves the light-induced cleavage of a 
bilayer-stabilizing group that results in liposomal contents release.  A prime example of this type 
of system is liposomes that contain 6-nitroveratryloxycarbonylated DOPE (NVOC-DOPE) lipids 
whose carbamate bonds undergo photolysis when irradiated with > 300-nm light to liberate 
carbon dioxide, 3,4-dimethoxy-2-nitrosobenzaldehyde, and DOPE.8,106,109,116  NVOC-DOPE 
lipids have also been formulated into liposomes with egg phosphatidylethanolamine (EPE).109,116  
Chandra et al. incorporated a photosensitive o-nitrobenzyl-based lipid into DSPC liposomes,117 
while Eastoe et al. modified cetyltrimethylammonium bromide (CTAB) liposomes with an 
anionic photolyzable surfactant, sodium 4-hexylphenylazosulfonate (C6PAS), that breaks down 
into alkane hexylbenzene and 4-hexylphenol (a weak surfactant) upon exposure to UV 
radiation.118  Very recently, Bonnet and coworkers mixed a ruthenium (Ru) complex with either 
dimyristoylphophatidylglycerol (DMPG) or dimyristoylphophatidylcholine (DMPC) to form 
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liposomes that undergo photofragmentation using 452-nm visible light.119  Upon irradiation, the 
Ru complex is broken down and forms a cationic aqueous complex that strongly interacts with 
the lipid membrane, causing partial liposome fusion and destabilization.119 
 A pseudo-subset of photofragmentation is photooxidative cleavage, which is 
characterized by an increase in membrane permeability due to the oxidative cleavage of 
plasmenylcholine from single-chain surfactants upon near-infrared light (630–820 nm) 
exposure.106  Plasmenylcholines are naturally occurring vinyl ether lipids that help protect animal 
cells from singlet-oxygen species caused by UV light.89,109  Upon photooxidation, the 
plasmalogen vinyl ether linkage liberates single-chain surfactants (lysolipids and fatty aldehydes) 
that cause a lamellar-to-hexagonal phase change in the bilayer.106  A key component in these 
photooxidative liposomal formulations is a photosensitizer (e.g. zinc phthalocyanine, tin 
oxtabutoxyphthalocyanine, bacteriochlorophyll) that harnesses the near-infrared radiation and 
oxygen to produce reactive-oxygen species.106,120  Thompson et al. found that when 
bacteriochlorophyll a was incorporated into 1-alk-1’-enyl-2-palmitoyl-sn-glycero-3- 
phosphocholine (PlasPPC)/DPPC liposomes, 100% of the encapsulated cargo (calcein) was 
released in less than 20 minutes.109  The single-chain surfactant products that result from 
photooxidation also laterally diffuse within the bilayer, separating into domains that create 
defects or pores and cause liposomal fusion and destabilization.109  To amplify the initial 
photoresponse, Wymer et al. coupled the release of Ca2+ from photooxidized diplasmalogen 
liposomes with PLA2 (a calcium-dependent enzyme) to then trigger the subsequent 
destabilization of another population of calcein-containing liposomes in a cascade-type 
mechanism.10  The Ca2+-loaded liposomes were composed of a synthetic diplasmalogen  
(1,2-di-o-hexadec-1’(Z)-enyl-sn-glyceryl-2-phosphocholine, (DPPlsCho)), dihydrocholesterol 
(DHC), and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) conjugated to 
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PEG5000.8,109  The calcein-containing liposomes were conventional formulations of DPPC that 
ruptured upon calcium-activation of PLA2 and subsequent PLA2-induced destabilization of the 
DPPC bilayer.8,109 
 All of the phototriggering mechanisms discussed thus far are irreversible in nature and 
result in the rapid release of liposomal payloads.  Therefore, to exert more control over these 
types of systems, liposomes that destabilize upon photoisomerization may be desirable to 
effectively “gate” the containment/release of encapsulated contents.  The majority of 
photoisomerizable liposomes are based on azobenzene derivatives such as 
[1,2-(4-n-butylphenyl)azo-4-(γ-phenylbutyroyl)-glycero-3-phosphocholine] or Bis-Azo PC, 
which is a photochromic lipid that undergoes cis-trans isomerization upon irradiation with 
near-UV light.8,106,121-122  More specifically, the thermodynamically stable trans form of Bis-Azo 
PC allows tight packing of the lipid in the bilayer; however, after photoisomerization to the 
bulky cis-isomer, the bilayer becomes disrupted and more permeable to release the entrapped 
cargo.106,109  Bisby et al. studied Bis-Azo PC/DPPC liposomes and found that addition of 
cholesterol affects the wavelength range over which these liposomes can be phototriggered.121  
The trans-to-cis isomerization is achieved through irradiation with 320-nm UV light, and the 
cis-to-trans reversal is obtained with 430-nm visible light or by heating, thus demonstrating the 
reversibility of this system.109  Impressively, Morgan et al. showed that Bis-Azo PC/DPPC 
liposomes completely released encapsulated calcein within milliseconds of phototriggering.109  
Recently, a negatively-charged alkyl surfactant was prepared into liposomes with a 
positively-charged azobenzene-conjugated surfactant to produce cationic liposomes (50–200 nm 






 The lower pH conditions of tumors is due to the accumulation of lactic acid and ATP 
hydrolysis products which result from elevated metabolic processes of cancerous cells under 
hypoxic conditions.3,124  The original and much less viable strategy of utilizing the general acidic 
microenvironment of tumors to trigger pH-sensitive liposomes was rather unsuccessful: the 
tumor interstitium is only about pH 6.5 at the lowest, which is not very different from 
physiological pH 7.1–7.4 and makes it difficult to design pH-triggerable liposomes that remain 
stable in the blood but then destabilize in the tumor.3,8,124  But, it has been reported that the pH of 
tumors can be artificially lowered even more (about 1 pH unit lower) by injecting glucose into 
the bloodstream, which increases the production of lactic acid.71 
 A more practical approach is to utilize the acidic endosomal environment (pH 5.5) to 
trigger the release of the drug cargo from the liposomes after internalization by the endosomes.  
Moreover, with the popularity of active targeting, it should be considered that the fate of 
liposomes with receptor-targeted ligands is also endocytotic uptake.  While endocytosis can 
occur in the absence or presence of ligand, it is facilitated by the presence of cationic ligands, 
and internalization is highly dependent on the size of the DDS (ideally between 100–200 nm).55   
Eventually, endocytosis results in lysosomal degradation (pH 4.5) and destruction of the 
liposomes and their precious drug cargo.8,71  (However, it should be noted that some drugs are 
quite stable in endosomes/lysosomes such as anthracyclines and doxorubicin.8)   Thus, this 
strategy has resulted in the use of fusogenic liposomes whose lipids undergo a phase transition, 
from a lamellar bilayer (Lα) to inverted hexagonal (HII) micelles, and are able to fuse with the 
endosomal membrane to deliver drugs into the cytoplasm of cancerous cells.8  Consequently, 
fusogenic lipids (e.g. DOPE) have become a benchmark in the design of pH-sensitive liposomal 
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formulations, which also include any combination of stabilizing lipids, polymers, amphiphilic 
molecules, and/or targeting ligands (e.g. antibodies, peptides).   
 Unfortunately, the benefits that active targeting ligands provide liposomes (especially 
site-specific direction and internalization into cancerous cells) have been challenging to reap 
because of the necessary inclusion of a PEG-protected liposomal periphery.  The PEGylated 
exterior may hamper the fusogenic potential of these liposomes by sterically preventing the 
contact-driven fusion and destabilization events, and also decrease liposome uptake into cells.8,71  
Furthermore, the protective PEG corona also shields the buried targeting moieties (anchored on 
the bilayer surface) from their respective tumor cell-specific receptors, thus reducing cell 
internalization.8  In response, targeting ligands were attached to the distal end of PEG chains for 
better ligand-receptor interaction; however, some research has shown that this approach 
compromises the protective cover of the PEG corona and increases liposome immunogenicity.3,8  
Due to these types of challenges, the evolution of pH-responsive liposomes has lead to highly 
complex, multifunctional systems (e.g. detachable PEG, cell-penetrating moiety).3 
 pH-sensitive liposomes are most commonly composed of DOPE and weakly acidic 
amphiphiles, such as oleic acid or cholesteryl hemisuccinate (CHEMS).3  As a case in point, the 
first pH-sensitive liposomes were composed of oleic acid and DOPE whose bilayer 
destabilization occurred at pH 6.5, resulting in earlier drug release outside of the cytoplasm or at 
the onset of endocytosis.124-128  To delay drug delivery, a DOPE and CHEMS mixture can be 
prepared into liposomes so that the bilayer permeability does not increase until the lysosomes are 
reached at around pH 5.5.124,129-130  Liposomes composed of DOPE/CHEMS were eventually 
modified with the addition of a hydrophilic polymer, such as mPEG2000-DSPE, to increase their 
circulation time in vivo.3,131-133  Another DOPE/CHEMS liposome system incorporated an 
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antibody (EGFR) to the distal tip of the PEG-lipid conjugate,134 while other liposomes have used 
folate and transferrin as active targeting ligands.3,135-137   
 As briefly alluded to earlier, the triggered loss of the PEG coating after reaching the 
tumor would be highly advantageous, because the obstacles/problems presented by 
sterically-stabilized liposomes could be overcome if the PEG was detachable.  Szoka and 
coworkers138-139 present a good example of an efficient sheddable-PEG liposome system that is 
composed of DOPE and distearoyl glycerol conjugated to detachable PEG through a diorthoester 
bond, which undergoes rapid hydrolysis around pH 5.5.3  Some researchers believe that 
exogenous administration of cysteine to cleave thiol-conjuated PEG is more advantageous than 
mild acidic pH or matrix metalloproteinase triggers, because it allows external and precise 
control over the shedding of PEG.85,140  Blending various pH-sensitive lipids into liposomal 
formulations and even conjugating lipids to different molecular functionalities provides a way to 
tune or adjust the destabilization behavior of these triggerable liposomes to release their contents 
at an optimal pH range.124  While pH-sensitive liposomes, and liposomes in general, offer this 
rather simplistic method of modification (i.e. easily incorporate different lipids/modifiers), it can 
often involve major synthetic overhauls or brand new synthetic routes.  In summary, the 
evolution of pH-sensitive liposomes has lead to highly complex, multifunctional systems whose 
behavior has not yet been well characterized, especially in vivo.3   
1.5 Enzyme-activated Liposomes 
1.5.1 Preceding Prodrug Examples 
 It is widely known that chemotherapeutic agents wreak havoc on healthy tissue due to 
their poor selectivity, and their narrow therapeutic index and propensity to induce multidrug 
resistance with prolonged treatments add to the challenges surrounding the administration of 
these toxic drugs.9  For decades now, scientists have been developing an array of enzymatically 
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triggered prodrug formulations to improve the bioactivation of these masked anticancer agents at 
tumor sites and to address the other problems cited above.   
 Prodrugs and bioactivatable drugs are inactive (or less potent) compounds that require 
transformation in vivo to their active metabolite in order to exhibit its pharmacological effects.141  
Both endogenous and nonendogenous enzymes have been used to activate produgs, and a large 
number of these systems were discussed in an extensive 2004 review by Rooseboom et al.9  As 
outlined in this document, the endogenous enzymes are categorized into four distinct classes 
according to the International Union of Pure and Applied Chemistry (IUPAC): Class 1 are the 
oxidoreductases, Class 2 are the transferases, Class 3 are the hydrolases, and Class 4 are the 
lysases.  Even though only a few different enzymatically-triggered liposome delivery systems are 
reported in the literature, the precedent set forth by prodrug development has pioneered the path 
for this young field. 
 Alkaline phosphatase is a widely specific enzyme that is found in serum and bound to 
cellular membranes, catalyzing the hydrolysis of phosphoric esters to alcohols and phosphates.9  
The abundance and wide distribution of alkaline phosphatase in living organisms limits its use to 
locally activate prodrugs, except when uses in conjunction with (antibody–, gene–, or virus–) 
directed enzyme prodrug therapies.9  S-2-(3-Aminopropylamino)-ethylphosphorothioic acid 
(Amifostine) is a clinically used anticancer prodrug that undergoes bioactivation via 
dephosphorylation by alkaline phosphatase.9   
 Matrix metalloproteinase–2 and –9 (MMP–2, MMP–9) are extracellar enzymes that are 
over-expressed in a variety of cancers and break peptide bonds in nonterminal amino acids.1,142  
Kline et al. synthesized both peptidic and sequence-similar peptidomimetics enzyme prodrugs to 
determine the best substrate(s) for the proteinases.143  One issue with the development of 
prodrugs is retention of the drug’s activity after bioactivation.  For example, prodrugs containing 
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the peptide sequence acetyl L-prolyl-L-leucyl-glycyl-L-leucine (AcProLeuGlyLeu) would 
strongly resemble the natural substrates of MMPs; however, a portion of the leucine residue 
remains on the drug after cleavage by the enzyme.143  Depending on the drug, activity can be lost 
lowering its therapeutic efficacy.  Fortunately, Doxorubicin tolerates conjugation with leucine, 
and in fact, L-leucyldoxorubicin (LeuDox) shows strong antitumor activity both in vitro and in 
vivo.143  As a result, doxorubicin and several other drugs were formulated into prodrugs for 
MMP–2 and –9.  Similarly, Chau et al. prepared new dextran-peptide-methotrexate conjugates to 
deliver chemotherapeutic agents selectively to tumor sites by targeting MMP–2 and –9.144   
 Due to their wide distribution in the human body, carboxylesterases are mainly used in 
antibody– or gene–directed enzyme prodrug therapies.9  Carboxylesterases aid in the conversion 
of carboxylic esters to alcohols and carboxylic acids, but they are also capable of hydrolyzing 
amides, thioesters, phosphoric acid esters, and acid anhydrides.9  Paclitaxel-2-ethylcarbonate is 
an example of a prodrug that has been converted to its cytotoxic parent drug, Paclitaxel (Taxol), 
by carboxylesterase present in rat serum.9  It seems relevant to also comment on the role of 
esterases in prodrug activation and the stability of prodrug ester bonds in vivo.  The ubiquity of 
esterases in the body is undisputed, and the incomplete catalog of their whereabouts and the 
various types of esterases just compounds the problem of being able to fully exploit their use as 
bioactivating agents.9,145  Consequently, the design of esterase-sensitive prodrugs (i.e. those 
containing ester bonds) seems pointless, especially because of the added concern as to whether 
ester bonds are stable in biological systems.  A time-tested example of an ester bond persisting in 
a biological environment, however, is the prodrug acetylsalicylic acid or asprin.145  Another 
popular use of esterases, especially in the realm of nanoparticle-based drug delivery is to 
facilitate the removal of protective PEG chains from these delivery vehicles.  For example, Xu et 
al. modified pH-sensitive liposomes with PEG-lipid derivatives whose ester bonds were cleaved 
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upon esterase action, thus providing a way to selectively shed the PEG coating in order to 
achieve efficient contents release and long circulation times, simultaneously.146 
 In conclusion, the variety and myriad of enzymes that have been utilized to activate 
prodrugs proves their importance to the future of triggerable liposome delivery agents, not to 
mention other nanoparticle-based delivery systems as well.  Elastase17,147-148 and phospholipases 
C8,18,149 and A21,8,13,150-151 are other enzymes being explored for liposomal activation.  As more 
information is learned about the metabolism and microenvironment of cancer, the more these 
tumor-specific (endogenous) enzymes can be employed in liposome drug delivery and the further 
this field with go.  
1.5.2 Secretory Phospholipase A2 (sPLA2) 
 Enzyme overexpression in the extracellular environment of tumors is already well 
understood, clearly evidenced by the bounty of endogenous enzymes used to activate prodrugs.  
As pointed out by Andresen et al., all of the successful enzyme-triggered liposome delivery 
systems have utilized secretory enzymes that induce extracellular drug release.1  However, in this 
same review article, it is also made clear that other intracellular enzymes may be upregulated in 
cancer cells (versus healthy cells) and could potentially be targeted for drug release in the 
future.1  In fact, with increasing knowledge about the intricacies of tumor biology (i.e. 
intracellular composition) and the development of multifunctional liposome carriers, using 
intracellular enzymes to trigger drug release will undoubtedly be realized.  To date, though, two 
of the main enzymes reported in the literature that initiate liposomal drug release extracellularly 
are secretory phospholipase A2 (sPLA2) and extracellular matrix metalloproteinases (MMPs), the 
latter being discussed in a later section.  
 Part of the phospholipase A2 superfamily, sPLA2 belongs to a subgroup of small secretory 
enzymes that range in size from 14–19 kDa and require millimolar concentrations of Ca2+ for 
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activation.1,152  The function of these enzymes is to catalyze the hydrolysis of the sn–2 ester bond 
in glycerophospholipids, producing free fatty acids and lysophospholipids.1,152  sPLA2 is 
over-expressed “many-fold”150 in various cancers such as prostate, breast, and pancreatic, with 
type IIA (sPLA2–IIA) being the most studied and the highest concentrated type in cancerous 
tissue.1,152  While the presence and upregulation of sPLA2 in tumors is undisputed, its role in the 
development of human cancer is still being elucidated; although, it has been suggested that 
sPLA2 over-expression is an indirect response to stimulation of inflammatory cytokines.152-153  
More importantly, sPLA2–IIA has been linked to the increased aggressiveness of tumors.153   
 Interestingly, aggregated phospholipids (e.g. liposomes and micelles) are more 
susceptible to sPLA2–catalyzed hydrolysis versus lipid monomers, which is highly dependent on 
lipid composition, morphology/arrangement, and especially membrane charge.1,153  sPLA2–IIA is 
highly specific towards anionic phospholipid membranes, compared to neutral membranes 
composed of zwitterionic lipids (e.g. phosphocholines) which induce virtually no enzymatic 
action from sPLA2–IIA.1,153  The large concentration of cationic residues on the sPLA2–IIA 
surface is responsible for this enhanced specificity towards anionic membranes.153  Fortunately, 
the surface of unperturbed, native mammalian cells is composed of mostly neutral lipids such as 
sphingomyelin, phosphatidylcholines, and cholesterol, which consequently makes healthy cells 
poor substrates for sPLA2–IIA–catalyzed degradation.153 
 In terms of developing sPLA2–activated liposome delivery agents, lipids of optimal 
charge and composition should be chosen and the liposome prepared in such a way as to 
maximize sPLA2 activity.  The necessary inclusion of protective PEG chains into liposomal 
formulations, for increased in vivo circulation times, actually enhances the activity of sPLA2 
toward these sterically stabilized liposomes.1  Conjugation of PEG to the positively charged 
amine of the phospholipid neutralizes the charge, resulting in a PEG-lipid conjugate with a net 
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negative charge from the phosphate group which promotes sPLA2 interaction.1  Moreover, the 
protective PEG coating does not seem to hinder the approach of sPLA2 enzymes to the liposome 
surface; on the contrary, these enzymes appear to readily penetrate the PEG corona and 
successfully hydrolyze the anionic lipids.1 
 sPLA2–activated liposomes that have been reported in the literature are either traditional 
drug-loaded formulations or composed of prodrug conjugates wherein the drug is incorporated 
into the phospholipid backbone and/or is the cytotoxic ether lipid component that results from 
sPLA2 hydrolysis.  After activation by sPLA2, traditional drug-loaded 
DSPC/DSPG/DSPE-PEG2000 liposomes expel bilayer-destabilizing lysolipids and fatty acids 
that enhance the permeability of nearby cellular membranes and facilitate intracellular uptake of 
the released drug cargo.13  This same idea was applied to a more complex, cascade-type system 
where DPPC liposomes were destabilized by PLA2 after another population of photosensitive 
liposomes released Ca2+ ions upon irradiation with 800-nm light (see discussion of 
light-triggered liposomes).1,8,10,109   
 Anticancer ether lipids (AELs) are a class of anticancer drugs that slow the progression of 
tumor growth without inducing myelosuppression or mutagenic effects.13  Prodrug versions of 
AELs, referred to as “proAELs” (e.g. proAEL–PC, proAEL–PG), have been incorporated into 
the bilayer of liposomes and only reveal their cytotoxic nature after activation by sPLA2.13  A 
proAEL thio-ester variant has also been reported.154  To further increase the anticancer punch of 
this treatment type, double proAELs have also been synthesized and prepared into liposomes.13  
In double proAELs, the sn–2 fatty acid chain is replaced with a drug (i.e. retinoids,11,13 
prostaglandins,13 chlorambucil12) so that the free AEL and drug are released after sPLA2 
hydrolysis.13  Cytotoxic retinoids have also been prepared into liposomes for sPLA2-triggered 
release.11  Composed of a cytotoxic lysolipid (AEL-like) conjugated to a retinoid (e.g. all-trans 
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retinoic acid, ATRA), these cytotoxic retinoid-based liposomes represent another type of “double 
dose” approach, much like the double proAELs.11  Liposomes composed of synthetic 
capsaicin-lipids undergo destabilization by a unique sPLA2–initiated intramolecular cyclization 
reaction that releases free capsaicin, an anticancer agent, from the phospholipid backbone.155  In 
this particular formulation, the sn–1 fatty acid position is substituted with capsaicin, and 
interestingly, the authors also report that these novel phospholipids spontaneously formed small 
unilamellar vesicles (liposomes) upon dispersion in a buffer with no sonication or extrusion 
needed.155    
1.5.3 Matrix Metalloproteinase (MMP) 
 MMPs are essential for malignant tumor growth, invasion, metastasis, and angiogenensis, 
as these zinc-dependent endopeptidases are responsible for the degradation of extracellular 
matrix components, a process necessary for cancer development and progression.1,142,156  While 
transmembrane MMPs exist, only extracellular MMPs (i.e. MMP–2 and MMP–9) have been 
exploited as endogenous stimuli for triggering liposomes.  MMP–2 (Gelatinase A) and MMP–9 
(Gelatinase B) are over-expressed in a variety of cancers, such as brain, breast, cervical, 
colorectal, and many more.1,143,156  These gelatinases are responsible for the degradation of 
basement membranes by catalyzing the hydrolysis of peptide bonds in nontermial amino acids.142  
The general amino acid substrate sequence recognized by MMPs is acetyl 
L-prolyl-L-leucyl-glycyl-L-leucine (AcProLeuGlyLeu).143  Like PEGylated liposomes activated 
by sPLA2, the much larger MMP–2 (72 kDa) and MMP–9 (92 kDa) enzymes can also penetrate 
the protective PEG layer and catalyze the hydrolysis of peptide substrates on the bilayer surface.1  
Once again, this finding validates the fact that enzymes, in general, must be able to access and 
effect their transformations on substrates hidden below the PEG corona. 
38 
 
 Even though PEG chains do not interfere with accessibility of the enzyme to the bilayer 
surface, they may cause reduced cellular uptake of liposomes and/or hamper the release of 
encapsulated cargo, particularly from fusogenic liposomes that require bilayer fusion to effect 
destabilization and rupture.  To this end, several systems have been reported that utilize MMP–2 
to facilitate the timely removal of PEG coatings from stealth liposomes.  Terada et al. coupled 
DOPE to a PEGylated MMP–2-cleavable peptide, and the lipid was prepared into liposomes with 
galactose-terminated PEG-DOPE lipids to selectively target hepatocellular carcinoma (HCC).23  
Their idea was that MMP–2 would facilitate dePEGylation of these liposomes once they reached 
HCC cells to achieve efficient cellular uptake.  Similarly, Hatakeyama et al. developed a system 
composed of a PEGylated MMP–2 cleavable peptide coupled to DOPE that was blended into 
liposomes with free DOPE.157  This modified multifunctional envelope-type nanodevice 
(MEND) was prepared in order to transport a condensed DNA/polycation complex for systemic 
gene delivery for cancer therapy.  A few years later, this system was improved upon by 
incorporating a pH-sensitive fusogenic GALA peptide (GALA/Chol-anchored) to control 
intracellular trafficking and to improve gene silencing both in vitro and in vivo.158 
 In 2005, the first report of MMP-triggered liposomes was published using MMP–9 to 
degrade lipopeptides that were integrated into DSPC liposomes, resulting in destabilization and 
subsequent cargo delivery.14  These lipopeptides were composed triple helical collagen-mimetic 
peptides coupled to stearic acid and made up about 10% of the liposomal bilayer.14  Later, some 
mechanistic studies of this system were performed, in which various lipopeptides  
(containing either stearic, oleic, or palmitic acid) were mixed with POPC 
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), DOPC, or DSPC.15  Finally, in 2009, an 
optimum formulation of 30% lipopeptide and 70% POPC liposomes was tested with HT-29 
(colorectal adenocarcinoma cells) and MCF-7 (breast adenocarcinoma cells), to find that the 
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latter cell line triggered contents from these liposomes because of its sufficient concentration of 
MMP–9.16     
1.6 A Redox-active Liposome Delivery System 
1.6.1 Rationale for Quinone-Lipid Design  
 Each individual component of the quinone-dioleoylphosphatidylethanolamine (Q-DOPE) 
lipid serves a specific purpose that enables the overall structure of the liposome to function as a 
viable drug delivery vehicle.  Phosphatidylethanolamine (PE) lipids provide the crucial lamellar-
to-inverted hexagonal (Lα-HII) phase transition needed to sufficiently destabilize the lipid bilayer 
and release the liposome contents into the surrounding environment.6  The mechanism by which 
this phase transition occurs is two-fold: First, disconnection between the liposome, or Lα phase, 
stabilizer (quinone) and the PE lipid reintroduces electrostatic interactions between the 
positively-charged amine and the negatively-charged phosphate group of the free PE; then, any 
contact between these now fusogenic lipids and another membrane surface (i.e. fusogenic or 
cellular) induces destabilization of the bilayer.159  Electrostatic attraction between the oppositely-
charged amine and phosphate groups decreases the area of the PE polar heads, resulting in cone-
shaped PE lipids that reorganize from a bilayer into reverse micelles.6   
 As these liposomes undergo destabilization, the removal of water from their surfaces is 
an important step in the membrane fusion process.  The first instance of DOPE dehydration 
occurs upon cleavage of the quinone stabilizer from the DOPE lipid,160-161 which is hypothesized 
to correspond to the “contraction” or “lag time” that was observed in the calcein release 
experiments (see Chapter 4).  Hydration repulsive forces prevent the close approach of 
liposomes; therefore, removal of water facilitates the ability of two or more liposomes to 
establish a zone of contact and finally achieve intermembrane interaction.160-161  The other key 
dehydration step occurs during formation of the HII-phase, reverse micelles that organize into 
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tube-like structures, requiring highly efficient packing—which precludes the presence of a large 
amount of water.160-161   
 Perhaps the most important component of the active-triggering mechanism, the 
redox-active quinone moiety serves two primary functions: (1) it stabilizes the liposome (or Lα 
phase) by inhibiting the DOPE phase transition from Lα to HII until reductive activation and (2) it 
provides a palette on which to add various functional groups that will tune the specificity and 
rate of liposome opening.  Furthermore, the biocompatibility of quinones has already been 
established with the presence of Coenzyme Q, Plastoquinone, Ubiquinones, Vitamin K, and 
other quinones in biological systems.162-163  For example, Coenzyme Q is known to function as a 
redox constituent in the mitochondrial oxidative phosphorylation system, transporting electrons 
between Complex I/II and Complex III.162  
 Precedents for using quinones, or more specifically trimethyl lock-based benzoquinone 
derivatives, as protecting groups has been reported in the literature for prodrugs35,164-166 and in 
dendritic systems38,167 from our laboratory.  Moreover, research has shown that murine NQO1 
reduces various quinones at rates dependent on the electronic structure of the quinone.  The 
quinone reduction potential relates to the rate of both reduction168-169 and lactonization26,28 
providing a useful measure for destabilization.  The quinone functionalities (ranging from 
electron-donating to electron-withdrawing) will also allow the liposomes to be tuned to different 
potentials in order to prevent cross-reactivity between our liposomes and other interfering 
enzymes and redox agents, so as to stave off premature release.   
1.6.2 Mechanism of Destabilization 
 The active release mechanism works via a disconnection between the phospholipid and 




 Our redox-triggered liposome delivery vehicles are composed of a redox-active quinone 
liposome stabilizer and a DOPE phospholipid, which disconnect after reduction via NQO1, a 
tumor-associated reductase.  
 
Scheme 1.1.  Cartoon illustration depicting the fundamental event involved in the active release 
mechanism of our redox-active liposomes.  
 
 In our system, the mechanism by which this Lα-HII phase transition occurs is a two-step process: 
First, the quinone undergoes a 2-electron reduction to the hydroquinone, which then initiates a 
spontaneous intramolecular cyclization/elimination that expels lactone molecules and free DOPE 
in the form of fusogenic liposomes (Scheme 1.1)  The “trialkyl lock,” which is located on the 
right side of the quinone (Y = CH3, R3 = CH3), accelerates cyclization to the lactone through the 
“gem-disubstituent effect”170 and conformational restriction known as “stereopopulation 
control.”26-37  When the trialkyl lock is absent, the rate of lactonization is 103 times slower.33  
However, Winans and Wilcox argued that conventional steric strain relief is the predominant 
factor for catalyzing lactonization.32  From empirical force field model calculations, they 
concluded that qualitatively at least 70% of the total free energy steric effect in this type of 
system comes from conventional steric strain relief, compared to the contribution from 
stereopopulation control (entropic factor).32   
 According to Winans and Wilcox, it is clear that Milstein and Cohen credited 
stereopopulation control with too much influence over the rate enhancement and grossly 
underestimated the effect of conventional steric strain relief.32  Nonetheless, Jung and Piizzi 
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1.6.3 NAD(P)H:quinone Acceptor Oxidoreductase (NQO1) 
 NAD(P)H:quinone acceptor oxidoreductase type 1 (NQO1) is a 62 kDa detoxifying, 
flavoenzyme that catalyzes the 2-electron reduction of quinones to hydroquinones, which 
protects animal cells from harmful and carcinogenic effects of free radicals resulting from 
one-electron reductions.24-25,173-175  This type 1 form is the predominate type of this enzyme in 
humans.9  While human NQO1 (hNQO1) is mainly present in the cytosol of cells, it is also 
located in the nucleus.176  Nakamura and Hayashi reported that NQO1 is even present in the 
plasma membrane of rat liver cells,177 which brings much hope to finding the presence of 
extracellular or membrane-bound hNQO1.  hNQO1 is over-expressed in tumors, such as those of 
the liver (4– to 19–fold), lungs (12– to 18–fold), breast (3–fold), and gastrointestinal tract (colon, 
3– to 4–fold), which makes this reductase enzyme an attractive facilitator for activating 
chemotherapeutic agents.9,24-25,173-174  The crystal structure of hNQO1 reveals four subunits 
(tetramer), each containing a noncovalently bound FAD cofactor molecule, and arranged as a 
pair of two homodimers.24-25,173-174  The active site, which is located at the interface of each 
dimer, is highly flexible and can accommodate various quinone substrates into its 360 Å3 
pocket.24-25,163  NAD(P)H also cycles in and out of this active binding site but must be released 
before the (quinone) substrate can bind.173  The “ping pong” mechanism of this two-electron 
reduction involves direct hydride transfers from NAD(P)H to FAD and then from FADH2 to the 
quinone.24-25,173-174 
 Mitomycin C and its aziridinylquinone analogues, Apaziquone (EO9) and Diaziquone 
(AZQ), are quinone-based bioreductive drugs activated by NQO1 that exhibit antitumor activity 
primarily by inducing DNA alkylation.9,163,165  The wide variety of quinone substrates that NQO1 
can metabolize is impressive, as NQO1 can also activate other quinoidal bioreductive drugs (e.g. 
Streptonigrin, Menadione) and even Tirapazamine and CB1954, which are nonquinoidal 
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bioreductive drugs.9  In addition to quinones, quinone epoxides, aromatic nitro and nitroso 
compounds, azo dyes, and chromium VI are also known substrates of NQO1.163   Quinones can 
also be used in the formulation of prodrugs as promoieties to release cytotoxic agents.  
Indolequinones have been coupled to antitumor drugs such as camptothecin and phosphoramide 
mustard.165  Benzoquinone-derived prodrugs that contain the TML have been used to facilitate 
the release of melphalan, semaxanib (SU5416), and 4-aminophenyl nitrogen mustard.35,165  This 
particular type of promoiety is the same “protecting group” or “liposome stabilizer” used in the 
design of our redox-active liposome delivery vehicles.  Finally, naphthoquinone- and 
benzoimidazolequinone-type promoieties have been used to transport phosphoramide mustard, 
which is then released by rearrangement of the imidazole electrons and via quinone-methide 
elimination, respectively, after bioreduction.165  For example, Flader et al. synthesized a series of 
(naptho– and benzimidazole–) quinone phosphorodiamidates that were designed to be activated 
by NQO1 to release a cytotoxic phosphoramide mustard alkylating agent for DNA 
crosslinking.178-179  Therefore, the extensive literature about NQO1, covering everything from 
NQO1 overexpression in tumors to the prodrugs developed for NQO1-bioactivation, has paved 
the way for the development of our NQO1-triggered liposomal delivery system. 
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2.1.1 Materials and General Considerations 
 
 All reagents were purchased from Sigma-Aldrich or TCI America and used as received.  
Compounds 1a&b, 1d, 1h, 2a–d, and 2g are commercially available.  Column chromatography 
was performed using either silica gel purchased from Sigma-Aldrich (pore size 60 Å, 200–400 
mesh) or with a Biotage FlashMaster Personal Chromatography System with SPE ISOLUTE 
FLASH Silica II disposable columns (pore size 60 Å, particle diameter 40–63 µm).  1H NMR 
spectra were recorded at either 300 or 400 MHz, and 13C NMR spectra were recorded at 75.47 or 
100.61 MHz using a Bruker spectrometer.  ESI-MS spectra were obtained using an Applied 
Biosystems QSTAR XL quadrupole time-of-flight mass instrument with acetonitrile as solvent.    
2.1.2 Synthetic “Maps” 
 
Scheme 2.1. Synthesis of quinone compounds 7 & 8 intended for self-immolative spacer.   
 





Scheme 2.3. General Synthesis of Simple Quinones 1a–h, Quinone Propionic Acids 4a–h, Quinone Succinimide Propionates 5a–d, 
and Quinone-DOPE lipids 6a–d. 
aNBS oxidation applies only to 2b→1c, 2e→1e, 2f→1f; compound 2g underwent oxidative iodination to 1g.  b2e–g do not undergo 
lactonization.  Also note the following transformations (not explicitly shown): Bromination of 2a→2e and 2b→2f by Br2/HOAc; 
Bromine ion displacement of 4e→4f via n-PrNH2/MeOH; Acetylation of 3a→3f using Ac2O/dry pyridine; Iodination of 3f→3g by 
I2/CF3CO2Ag in DCM; Deacetylation of 3g→3h via HCl/MeOH. 
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2.1.3 Experimental Details & Characterization Data 
 The synthetic procedures for compounds 3d and 4d are described in a previous 
publication from our group.1  The melting point of 3d is 172.5–175 °C (corrected), and 4d is 
112.9–114.8 °C (corrected).  Literature references for the following synthetic procedures are 
either cited at the end of the bold headings or next to the number designation of the compound.  
General procedure for quinones 1c, e, f, and quinone propionic acids 4a–c, g:2  
(4a).  In a typical procedure, a solution of NBS (0.853 g, 4.8 mmol) in 10 mL of acetonitrile was 
added dropwise to a stirred solution of 3a (1.0 g, 4.5 mmol) in 50 mL of 10% aqueous 
acetonitrile.  The reaction mixture was stirred at room temperature for 90 min, diluted to 110 mL 
with water, and extracted with ether (4 × 30 mL).  The combined ether extracts were washed 
with 50 mL of water and saturated brine (2 × 50 mL) and dried over MgSO4.  Solvent removal 
with the aid of a rotary evaporator provided a yellow oil, which solidified after refrigeration.  
Recrystallization from chloroform/hexane afforded 0.755 g (70%) of 4a as a bright yellow solid.  
Mp. 69–72 °C (corrected).  1H NMR (400 MHz, CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.00 (d, 
3H, CH3), 2.19 (s, 3H, CH3), 3.07 (s, 2H, CH2), 6.47 (s, 1H, quinone H).  13C NMR (100.61 
MHz, CDCl3) δ 14.5 and 15.5 (quinone CH3), 29.1 (geminal CH3), 38.2 (quaternary C), 47.3 
(CH2), 134.8 (quinone CH), 140.4 and 143.7 (quinone C-CH3), 150.8 (quinone C-propionic side 
chain), 178.2 (C=O), 188.2 and 189.6 (quinone C=O).  HRMS (ESI) m/z [M−H]−, calcd = 
235.0970 (calcd for C13H15O4), obsd = 235.0975, −2.3 ppm error. 
(4b).  From starting material, 3b.  Recrystallized from hexane.  Yield 87%.  Mp. 103.0–104.5 °C.  
1H NMR (400 MHz, CDCl3) δ 1.44 (s, 6H, geminal CH3), 1.94, 1.96, and 2.15 (s, 3H, CH3), 3.03 
(s, 2H, CH2).  13C NMR (100.61 MHz, CDCl3) δ 12.2, 12.6, and 14.4 (quinone CH3), 28.9 
(geminal CH3), 38.1 (quaternary C), 47.4 (CH2), 138.5, 139.2, and 143.1 (quinone C-CH3), and 
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152.2 (quinone C-propionic side chain), 179.1 (C=O), 187.6 and 191.0 (quinone C=O).  HRMS 
(ESI) m/z [M−H]−, calcd = 249.1126 (calcd for C14H17O4), obsd = 249.1132, −2.6 ppm error. 
(4c).  From starting material, 3c.  Recrystallized from hexane.  Yield 56%.  Mp. 101.3–103.2 °C.  
1H NMR (400 MHz, CDCl3) δ 1.33 (s, 6H, geminal CH3), 2.01 (d, 6H, CH3), 2.96 (s, 2H, CH2), 
6.54 (s, 1H, CH).  13C NMR (75.47 MHz, CDCl3) δ 11.8 and 12.6 (quinone CH3), 28.0 (geminal 
CH3), 36.8 (quaternary C), 44.9 (CH2), 132.2 (quinone CH), 139.7 and 142.4 (quinone C-CH3), 
152.9 (quinone C-propionic side chain), 177.6 (C=O), 187.4 and 187.9 (quinone C=O).  HRMS 
(ESI) m/z [M−H]−, calcd = 237.1128 (calcd for C13H17O4), obsd = 237.1126, 1.0 ppm error. 
(1c).  From starting material, 2b.  No purification necessary.  Yield 88%.  Mp. 28.5–29.8 °C.  1H 
NMR (400 MHz, CDCl3) δ 2.01, 2.03, and 2.04 (d, 3H, CH3), 6.56 (q, 1H, CH).  13C NMR 
(100.61 MHz, CDCl3) δ 12.0 and 12.3 (adjacent CH3), 15.8 (CH3), 133.0 (CH), 140.7, 140.9 and 
145.3 (C-CH3), 187.4 and 187.8 (C=O).  HRMS (ESI) m/z [M+H]+, calcd = 151.0760 (calcd for 
C9H11O2), obsd = 151.0753, 4.9 ppm error. 
(1e).  From starting material, 2e.  Recrystallized from ethanol/water (yield 62%) and then 
chromatographed using dichloromethane/hexanes (1:1) to remove the doubly brominated 
species.  Mp. 55.2–56.3 °C (corrected).  1H NMR (400 MHz, CDCl3) δ 2.09 (d, 3H, CH3), 2.25 
(s, 3H, CH3), 6.78 (q, 1H, CH).  13C NMR (100.61 MHz, CDCl3) δ 16.0 and 17.1 (CH3), 132.5 
(CH), 135.9 and 145.9 (C-CH3), and 146.0 (C-Br), 179.2 and 184.5 (C=O).  HRMS (ESI) m/z 
[M+H]+, calcd = 214.9708 (calcd for C8H8O2 Br), obsd = 214.9702, 3.0 ppm error. 
(1f).  From starting material, 2f.  Recrystallized from ethanol.  Yield 47%.  Mp. 78.2–78.6 °C.  
1H NMR (400 MHz, CDCl3) δ 2.06 and 2.09 (q, 3H, CH3), 2.23 (s, 3H, CH3).  13C NMR (100.61 
MHz, CDCl3) δ 12.64, 13.17 and 17.09 (CH3), 135.51 (C-Br), 140.90, 140.94 and 145.67 (C-
CH3), 179.48 and 184.34 (C=O).  HRMS (ESI) m/z [M+H]+, calcd = 228.9865 (calcd for 
C9H10O2Br), obsd = 228.9869, −1.6 ppm error. 
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(4g).  From starting material, 3h (grease-contaminated).  Even though TLC (16:4:1 hexs/ethyl 
acetate/acetic acid) only showed one spot, 4g was loaded onto a 10 g/25 mL Flash SI II column 
(FlashMaster) and initially flushed with hexanes to remove any residual grease from the starting 
material.  4g was then eluted off the column with 1:4 ethyl acetate/hexanes to yield 0.023 g 
(60%) as a yellow viscous liquid.  1H NMR (400 MHz, CDCl3) δ 1.44 (s, 6H, geminal CH3), 2.18 
(s, 3H, CH3), 2.24 (s, 3H, CH3), 3.02 (s, 2H, CH2).  13C NMR (100.61 MHz, CDCl3) δ 14.60 and 
22.12 (quinone CH3), 28.56 (geminal CH3), 38.66 (quaternary C), 47.20 (CH2), 121.61 (quinone 
C-I), 139.40 (quinone C-CH3), 150.46 (quinone C-propionic side chain), 152.68 (quinone C-
CH3), 177.73 (C=O), 183.22 and 183.65 (quinone C=O).  HRMS (ESI) m/z [M-H]−, calcd = 
360.9921 (calcd for C13H14O4I), obsd = 360.9942, −5.8 ppm error.      
(1g).3  A solution of 2g (1.0 g, 7.34 mmol) and iodine (1.86 g, 7.34 mmol) in 13 mL of ethanol 
was stirred and heated to 60 °C under a condenser to prevent any loss of solvent.  To this 
solution, 4 mL of 30% hydrogen peroxide diluted with 2 mL of ethanol was added slowly over a 
2 h period (1 mL was added dropwise every 20 min).  The mixture was stirred at 70 °C for an 
additional hour and was then cooled to 0–5 °C using an ice-salt bath.  The dark brown solid was 
collected via vacuum filtration, washed successively with 40 mL of a 5% NaHSO3 solution 
(which turned the solid orange), 25 mL of water, and 5 mL of cold (0–5 °C) 70% aqueous 
methanol.  The crude product was dried and then recrystallized from hexanes to yield 0.710 g 
(38%) of 1g as bright, shiny orange crystalline flakes.  Mp. 70.4–71.6 °C (corrected).  1H NMR 
(400 MHz, CDCl3) δ 2.07 and 2.11 (q, 3H, CH3), 2.32 (s, 3H, CH3).  13C NMR (100.61 MHz, 
CDCl3 ) δ 12.61, 13.76, and 22.90 (CH3), 121.48 (C-I), 140.04, 140.80, and 152.12 (C-CH3), 
180.34 and 183.02 (C=O).  HRMS (ESI) m/z [M+H]+, calcd = 276.9726 (calcd for C9H10O2I), 
obsd = 276.9720, 2.3 ppm error. 
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(2e).4  A solution of bromine (1.1 g, 6.88 mmol) in 3.4 mL of acetic acid was added dropwise to 
a stirred solution of 2a (1.0 g, 7.25 mmol) in 20.3 mL of acetic acid.  The mixture was stirred for 
24 h* at room temperature, and then the acetic acid was rapidly removed (20 min) with the aid of 
a rotary evaporator.  The crude material was recrystallized from 40% ethanol in water to produce 
a brownish-white solid (0.9 g, 60%).  *NOTE: The literature reference4 indicates a reaction 
duration of 5 h, most likely to avoid generation of the doubly brominated species; however, 
following the reaction progress by TLC revealed the presence of the doubly brominated species 
even after only 2 h.  Therefore, the purified product 2e is composed of about 6% (by 1H NMR) 
of the doubly brominated species.  Mp. 135–138 °C (corrected).  1H NMR (400 MHz, CDCl3) δ 
2.20 and 2.34 (s, 3H, CH3), 4.35 and 5.17 (s, 1H, OH), 6.72 (s, 1H, aryl H).  13C NMR (75.47 
MHz, acetone-d6) δ 16.6 and 16.7 (CH3), 110.8 (C–Br), 115.8 (CH), 125.6 and 126.2 (C-CH3), 
147.3 and 148.0 (C–OH).  HRMS (ESI) m/z [M−H]−, calcd = 214.9707 (calcd for C8H8O2Br), 
obsd = 214.9713, −3.0 ppm error. 
(2f).4  A solution of bromine (1.0 g, 6.3 mmol) in 3.1 mL of acetic acid was added dropwise to a 
stirred solution of 2b (1.0 g, 6.6 mmol) in 38 mL of acetic acid.  The reaction mixture was stirred 
at room temperature for 5 h, and then the acetic acid was rapidly removed (20 min) with the aid 
of a rotary evaporator.  The crude material was recrystallized from 45% ethanol in water to 
produce a blackish-orange solid, which was then washed with chloroform to remove the black 
impurities.  The purified product (2.61 g) was achieved in 60% yield.  Mp. 156–158 °C 
(decomposes, blackens).  1H NMR (400 MHz, CDCl3) δ 2.16, 2.24, and 2.34 (s, 3H, CH3), 4.30 
and 5.29 (s, 1H, OH).  13C NMR (75.47 MHz, CDCl3) δ 12.28, 13.02 and 16.26 (CH3), 110.60 
(C-Br), 120.41, 121.68 and 122.95 (C-CH3), 144.33 and 145.48 (C–OH).  HRMS (ESI) m/z 
[M−H]−, calcd = 228.9863 (calcd for C9H10O2Br), obsd = 228.9869, −2.8 ppm error. 
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(2h).5  1h (3.0 g, 16.5 mmol) was dissolved in a mixture of 45 mL of ether and 23 mL of 
methanol and was then added at room temperature to a stirring solution of sodium borohydride 
(3.12 g, 82.4 mmol) in 89 mL of water.  After 1 h of stirring, the mixture was poured into a 
separatory funnel, and the layers were allowed to separate.  To help better distinguish between 
layers, 30 mL of ether was added and then the ether layer was removed.  The aqueous phase was 
extracted again with 30 mL of ether.  The aqueous layer was then acidified with the slow 
addition of 37% HCl and extracted with ether (2 × 30 mL).  The combined organic extracts were 
washed with saturated brine (2 × 75 mL) and dried over MgSO4.  Solvent removal with a rotary 
evaporator gave 2.46 g (81%) of the hydroquinone as a whitish-orange solid.  The crude material 
was used directly in the preparation of 3e.  Mp. 75.4–76.5 °C.  1H NMR (400 MHz, CDCl3) δ 
2.18 (s, 3H, CH3), 3.89 and 3.92 (s, 3H, OCH3), 5.13 and 5.29 (s, 1H, OH), 6.49 (s, 1H, aryl H).  
13C NMR (100.61 MHz, CDCl3) δ 15.4 (CH3), 60.8 and 60.9 (OCH3), 111.4 (benzene CH), 119.4 
(benzene C-CH3), 137.2 (C–OCH3), 139.1 (C–OH), 140.4 (C–OCH3), 141.6 (C–OH).  HRMS 
(ESI) m/z [M+H]+, calcd = 185.0815 (calcd for C9H13O4), obsd = 185.0808, 4.0 ppm error. 
(3a).5  Methanesulfonic acid (20 mL) was heated to 70 °C in an oil bath with stirring.  Once this 
temperature was reached, 2a (2.0 g, 14.5 mmol) and 3,3-dimethylacrylic acid (1.55 g, 15.5 
mmol) were added and the reaction continued to stir at 70 °C for 2 h.  The mixture diluted to 200 
mL with water and extracted with ethyl acetate (3 × 50 mL).  The extracts were washed with 100 
mL of water, saturated NaHCO3 solution (2 × 100 mL), and 100 mL of saturated brine and dried 
over MgSO4.  Solvent removal with the aid of a rotary evaporator gave a tan solid, which was 
recrystallized from 40% CHCl3 in hexane to give 2.14 g (67%).  Mp. 144.5–145.7 °C.  1H NMR 
(400 MHz, CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.23 and 2.38 (s, 3H, CH3), 2.57 (s, 2H, CH2), 
4.50 (s, 1H, OH), 6.73 (s, 1H, aryl H).  13C NMR (100.61 MHz, CDCl3) δ 14.4 and 15.9 
(benzene CH3), 27.7 (geminal CH3), 35.4 (quaternary C), 46.0 (CH2), 116.8 (benzene C-CH3), 
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122.0 (benzene CH), 122.5 (benzene C-CH3), 128.6 (benzene C-lactone), 144.8 (C–O), 149.2 
(C–OH), 168.7 (C=O).  HRMS (ESI) m/z [M−H]−, calcd = 219.1020 (calcd for C13H15O3), obsd 
= 219.1026, −2.9 ppm error. 
(3b).5  Methanesulfonic acid (100 mL) was heated to 70 °C in an oil bath with stirring.  Once this 
temperature was reached, 2b (10.0 g, 65.7 mmol) and 3,3-dimethylacrylic acid (7.5 g, 74.9 
mmol) were added and the reaction continued to stir at 70 °C for 2 h.  The mixture was diluted to 
1250 mL with water and extracted with ethyl acetate (3 × 250 mL).  The extracts were washed 
with 400 mL of water, saturated NaHCO3 solution (2 × 100 mL), and saturated brine (2 × 150 
mL) and dried over MgSO4.  Solvent removal with the aid of a rotary evaporator gave a tan solid, 
which was purified by washing with 30% CHCl3 in hexane to give 12.0 g (83%).  Mp. 180–182 
°C.  1H NMR (400 MHz, CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.18, 2.22, and 2.36 (s, 3H, CH3), 
2.55 (s, 2H, CH2), 4.51 (s, 1H, OH).  13C NMR (75.47 MHz, CDCl3) δ 12.5, 12.7, and 14.7 
(benzene CH3), 27.8 (geminal CH3), 35.6 (quaternary C), 46.2 (CH2), 119.3, 122.2, and 123.5 
(benzene C-CH3), 128.3 (benzene C-lactone), 143.6 (C–O), 149.1 (C–OH), and 169.3 (C=O).  
HRMS (ESI) m/z [M−H]−, calcd = 233.1177 (calcd for C14H17O3), obsd = 233.1183, −2.7 ppm 
error. 
(3e).5  Methanesulfonic acid (18 mL) was heated to 70 °C in an oil bath with stirring.  Once this 
temperature was reached, 2h (1.5 g, 8.14 mmol) and methyl 3,3-dimethylacrylate (0.976 g, 8.55 
mmol) were added and the reaction continued to stir at 70 °C for 2 h.  The mixture was diluted to 
135 mL with water and extracted with ether (2 × 100 mL).  The extracts were washed with 80 
mL of water, saturated NaHCO3 solution (4 × 25 mL), and 65 mL of saturated brine and dried 
over MgSO4.  Solvent removal with the aid of a rotary evaporator gave a tan solid, which was 
recrystallized from methanol to give 1.22 g (56%).  Mp. 158–161 °C.  1H NMR (400 MHz, 
CDCl3) δ 1.46 (s, 6H, geminal CH3), 2.34 (s, 3H, CH3), 2.58 (s, 2H, CH2), 3.91 and 3.97 (s, 3H, 
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OCH3), 5.74 (s, 1H, OH).  13C NMR (100.61 MHz, CDCl3) δ 13.7 (benzene CH3), 27.7 (geminal 
CH3), 35.8 (quaternary C), 45.9 (CH2), 61.2 and 61.5 (OCH3), 116.4 (benzene C-CH3), 126.4 
(C–O), 138.3 (benzene C-lactone), 138.4 (benzene C-OCH3) 138.6 (C–OH), 143.9 (benzene C-
OCH3), 167.7 (C=O).  HRMS (ESI) m/z [M+H]+, calcd = 267.1233 (calcd for C14H19O5), obsd = 
267.1227, 2.4 ppm error. 
(4h).5  Pyridinium dichromate (3.17 g, 8.45 mmol) was dissolved with stirring in 7 mL of DMF.  
To this solution, lactone 3e (0.5 g, 1.88 mmol) in 2 mL DMF was added at room temperature.  
After 4.5 h of stirring, the reaction mixture was diluted to 400 mL with water and extracted with 
ether (3 × 50 mL).  The combined organic extracts were washed with 40 mL of water and then 
saturated sodium bicarbonate (5 × 25 mL).  The combined bicarbonate washings were made 
slightly acidic by the addition of 37% HCl, and the resulting aqueous solution was extracted with 
ether (4 × 25 mL).  These organic extracts were washed with 30 mL of brine and dried over 
MgSO4.  Solvent removal with the aid of a rotary evaporator gave a yellow viscous residue 
(0.1733 g, 33%).  The crude material was then purified on a 10 g/25 mL Flash Si II column 
(60:1) using the FlashMaster chromatography system using hexanes / ethyl acetate / acetic acid 
(16:4:1) to give 22 mg (4%) as a yellow viscous residue.  1H NMR (400 MHz, CDCl3) δ 1.45 (s, 
6H, geminal CH3), 2.15 (s, 3H, CH3), 3.06 (s, 2H, CH2), 3.90 (s, 3H, OCH3), 3.96 (s, 3H, OCH3).  
13C NMR (100.61 MHz, CDCl3) δ 14.0 (quinone CH3), 28.9 (geminal CH3), 38.2 (quaternary C), 
47.2 (CH2), 60.4 and 60.9 (OCH3), 137.7 (quinone C-CH3), 142.4 and 145.3 (quinone C-OCH3), 
149.8 (C-propionic side chain), 177.9 (C=O), 184.5 and 186.3 (quinone C=O).  HRMS (ESI) m/z 
[M+H]+, calcd = 283.1182 (calcd for C14H19O6), obsd = 283.1176, 2.3 ppm error.     
(3c).  2c (3.2 g, 23 mmol) and 3,3-dimethylacrylic acid (4.6 g, 46 mmol) were dissolved in 250 
mL of toluene along with 1.3 mL of concentrated sulfuric acid, and the mixture was refluxed for 
2 h.  The reaction mixture was washed with water (2 × 100 mL), 5% NaHCO3 solution (4 × 100 
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mL), and brine solution (2 × 100 mL), and then the toluene layer was dried over MgSO4.  
Solvent removal with a rotary evaporator afforded a dark black solid, which was recrystallized 
from 30% CHCl3 in hexane to give 2.33 g (48%) of a tan crystalline solid.  Mp. 146.0–149.5 °C.  
1H NMR (400 MHz, CDCl3) δ 1.31 (s, 6H, geminal CH3), 2.17 and 2.25 (s, 3H, CH3), 2.57 (s, 
2H, CH2), 4.60 (s, 1H, OH), 6.61 (s, 1H, aryl H).  13C NMR (100.61 MHz, CDCl3) δ 11.8 and 
12.3 (CH3), 27.6 (geminal CH3), 33.1 (quaternary C), 43.7 (CH2), 107.8 (benzene CH), 122.6 
and 126.4 (C-CH3), 129.6 (C–O), 142.8 (benzene C-lactone), 150.2 (C–OH), 169.0 (C=O).  
HRMS (ESI) m/z [M−H]−, calcd = 219.1020 (calcd for C13H15O3), obsd = 219.1026, −2.9 ppm 
error. 
(4e).5  3a (1.0 g, 4.5 mmol) was dissolved in 37 mL of acetic acid, and with stirring at room 
temperature a solution of bromine (1.6 g, 10 mmol) in 6 mL of acetic acid was slowly added 
dropwise.  After the reaction had stirred for 23 h, the mixture was diluted to 215 mL with water 
and extracted with dichloromethane (3 × 25 mL).  The combined organic extracts were washed 
with 50 mL of water and then saturated NaHCO3 solution (5 × 40 mL).  The combined 
bicarbonate washes were made just slightly acidic by the slow addition of 37% HCl, and the 
resulting aqueous solution was extracted with dichloromethane (4 × 25 mL).  The combined 
organic extracts were washed with 50 mL of water and then dried with MgSO4.  Solvent removal 
with a rotary evaporator afforded a yellow viscous residue (1.13 g, 71%), which solidified 
(crystalline) after refrigeration.  The entire crude material was not purified as per the literature 
reference;5 however, a small-scale recrystallization was successfully achieved from 
dichloromethane/hexanes in order to obtain X-ray crystallographic data.  1H NMR (400 MHz, 
CDCl3) δ 1.47 (s, 6H, geminal CH3), 2.18 and 2.20 (s, 3H, CH3), 3.06 (s, 2H, CH2).  13C NMR 
(100.61 MHz, CDCl3) δ 14.6 and 16.6 (quinone CH3), 28.8 (geminal CH3), 38.7 (quaternary C), 
47.2 (CH2), 136.2 (C–Br), 139.7 and 144.0 (C-CH3), 152.5 (quinone C-propionic side chain), 
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178.2 (quinone C=O), 182.4 (C=O), 184.6 (quinone C=O).  HRMS (ESI) m/z [M−H]−, calcd = 
313.0075 (calcd for C13H14O4Br), obsd = 313.0080, −1.7 ppm error. 
(4f).5  4e (0.2 g, 0.635 mmol) was dissolved in 5.3 mL of methanol, and then propylamine (0.188 
g, 3.2 mmol) was added with stirring at room temperature.  The flask was tightly stoppered, and 
stirring was continued for 46 h.  The mixture was diluted to 74 mL with water, 5.3 mL of 5% 
HCl was added, and the resulting solution was extracted with ethyl acetate (3 × 15 mL).  The 
combined organic extracts were washed with 35 mL of saturated brine and then dried with 
MgSO4.  Solvent removal with a rotary evaporator afforded a deep red viscous residue, which 
was chromatographed on a silica gel column (50:1) using hexanes / ethyl acetate / acetic acid 
(16:4:1).  Concentration of the major red fraction afforded a viscous residue, which was taken up 
in 20 mL of dichloromethane and washed with water (2 × 40 mL) to remove acetic acid.  After 
drying with MgSO4, the solvent was removed with a rotary evaporator, which gave a red viscous 
residue (0.082 g, 43%).  1H NMR (400 MHz, CDCl3) δ 0.96 (s, 3H, propyl CH3), 1.45 (s, 6H, 
gem CH3), 1.59 (m, 2H, CH2CH2CH3), 2.02 (s, 3H, quinone CH3), 2.20 (s, 3H, quinone CH3), 
2.99 (s, 2H, CH2), 3.37 (t, 2H, NCH2).  13C NMR (100.61 MHz, CDCl3) δ 10.4 (quinone CH3), 
11.1 (propyl CH3), 15.2 (quinone CH3), 24.1 (CH2CH2CH3), 29.2 (geminal CH3), 38.1 
(quaternary C), 46.9 (N-CH2), 47.0 (CH2), 107.6 (quinone C-CH3), 143.1 (quinone C-
propylamine), 146.2 (quinone C-CH3), 146.4 (quinone C-propionic side chain), 177.3 (C=O), 
185.9 and 187.1 (quinone C=O).  HRMS (ESI) m/z [M+H]+, calcd = 294.1706 (calcd for 
C16H24NO4), obsd = 294.1699, 2.5 ppm error. 
(3f).6-7  To a stirred solution of 3a (0.2 g, 0.91 mmol) in 3.2 mL of dry pyridine, acetic anhydride 
(3.3 mL) was added at room temperature.  A drying tube was used to stopper the reaction, and 
the mixture was allowed to stir for 24 h.  Then the mixture was poured into 75 mL of cold water 
and extracted with ethyl acetate (3 × 50 mL).  The combined organic extracts were washed with 
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saturated brine (2 × 50 mL) and dried over MgSO4.  Solvent removal with a rotary evaporator 
afforded a brownish liquid (still contains pyridine), which was put under high-vacuum and then 
chromatographed on a silica gel column (50:1) using ethyl acetate / hexanes (1:4).  
Concentration of the middle fraction (Rf ≈ 0.30) afforded a colorless sticky residue (0.21 g, 
97%), which solidified into a whitish solid after refrigeration.  Mp. 86–90 °C (corrected).  1H 
NMR (400 MHz, CDCl3) δ 1.45 (s, 6H, geminal CH3), 2.12 and 2.25 (s, 3H, CH3), 2.36 (s, 3H, 
acetyl CH3), 2.59 (s, 2H, CH2), 6.81 (s, 1H, aryl H).  13C NMR (100.61 MHz, CDCl3) δ 15.0 and 
16.3 (benzene CH3), 20.4 (acetate CH3), 27.7 (geminal CH3), 35.5 (quaternary C), 45.7 (CH2), 
117.4 (benzene CH), 128.5 and 128.7 (benzene C-CH3), and 130.1 (benzene C-lactone), 145.1 
and 148.8 (benzene C–O), 168.0 (lactone C=O), 168.9 (acetate C=O).  HRMS (ESI) m/z 
[M+H]+, calcd = 263.1284 (calcd for C15H19O4), obsd = 263.1277, 2.8 ppm error. 
(3g).8  To an ice-cooled mixture of 3f (1.13 g, 4.30 mmol) and silver trifluoroacetate (1.09 g, 
4.94 mmol) in 28 mL of dichloromethane, a solution of I2 (1.00 g, 3.95 mmol) in 28 mL of 
dichloromethane was added under stirring.  After stirring for 3.5 h at room temperature, silver 
iodide (yellow precipitate) was vacuum-filtered off and washed with dichloromethane.  (Several 
filtrations might be necessary in order to completely remove silver iodide.)  The combined 
filtrate and washings were poured into a separatory funnel, washed with aqueous NaHCO3 (3 × 
150 mL) and water (2 × 150 mL), and then dried over MgSO4.  The solvent was removed with a 
rotary evaporator, and the crude material was purified on a silica gel column (25:1) using 
dichloromethane as the eluent.  Concentration of the first fraction (Rf ≈ 0.51) afforded a colorless 
sticky residue (1.0 g, 65%), which solidified into a whitish solid after refrigeration.  Mp. 160–
165 °C (corrected).  1H NMR (400 MHz, CDCl3) δ 1.45 (d, 6H, geminal CH3), 2.22 (s, 3H, 
benzene CH3), 2.31 (s, 3H, acetyl CH3), 2.36 (s, 3H, benzene CH3), 2.58 (d, 2H, CH2).  13C NMR 
(100.61 MHz, CDCl3) δ 15.2 and 20.5 (benzene CH3), 22.7 (acetyl CH3), 27.4 (geminal CH3), 
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36.3 (quaternary C), 45.7 (CH2), 90.7 (C–I), 129.0 and 129.3 (benzene C-CH3), 134.3 (benzene 
C-lactone), 144.3 and 148.3 (benzene C–O), 166.8 (acetyl C=O), 168.7 (lactone C=O).  HRMS 
(ESI) m/z [M+H]+, calcd = 389.0251 (calcd for C15H18O4I), obsd = 389.0244, 1.9 ppm error. 
(3h).9  3g (0.1 g, 0.258 mmol) was dissolved in a minimal amount of dichloromethane because 
its solubility in methanol is limited.  To this solution, 7.4 mL of methanol and then 0.3 mL of 
HCl were added with stirring.  The solution was allowed to stir at room temperature for 5 days; 
although, monitoring by TLC (eluent = DCM) for reaction completion is recommended.  The 
reaction was quenched with 10 mL of cold water and extracted with ethyl acetate (2 × 20 mL).  
The combined organic extracts were washed with 50 mL of brine and then dried over Na2SO4.  
The solvent was removed with a rotary evaporator, and the crude material was purified on a 25 
g/150 mL Flash Si II column (~300:1) using the FlashMaster chromatography system using 
chloroform/ethyl acetate (30:1) to give 36.2 mg (40%) as a white solid.  *The purified product 
was contaminated with grease but used anyway for the synthesis of 4g.  1H NMR (400 MHz, 
CDCl3) δ 1.47 (s, 6H, geminal CH3), 2.36 (s, 3H, benzene CH3), 2.47 (s, 3H, benzene CH3), 2.57 
(s, 2H, CH2), 4.61 (s, 1H, OH).  13C NMR (100.61 MHz, CDCl3) δ 14.7 and 22.0 (benzene CH3), 
27.5 (geminal CH3), 36.2 (quaternary C), 46.1 (CH2), 90.5 (benzene C-I), 122.2 and 126.8 
(benzene C-CH3) 129.5 (benzene C-lactone), 144.6 (benzene C-O), 148.6 (benzene C-OH), 
167.4 (lactone C=O).  HRMS (ESI) m/z [M+H]+, calcd = 347. 0145 (calcd for C13H16O3I ), obsd 
= 347.0138, 2.1 ppm error. 
General procedure for quinone succinimide propionates 5a–d:5 
(5c).  In a typical procedure, dicyclohexylcarbodiimide (0.440 g, 2.13 mmol) was added to a 
solution of quinone propionic acid 4e (0.594 g, 1.9 mmol) and N-hydroxysuccinimide (0.239 g, 
2.08 mmol) in 30 mL of dry THF at 0 °C under argon.  The mixture was stirred for 20 h and 
allowed to gradually warm to room temperature.  To remove dicyclohexylurea, the solution was 
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vacuum filtered, evaporated (with the aid of a rotary evaporator), treated with 10 mL of ethyl 
acetate, and vacuum filtered again.  This cycle was repeated three times, or until all of the 
dicyclohexylurea was removed.  Final evaporation of the solvent and recrystallization of the 
residue from ethyl acetate/hexanes afforded 0.527 g (68%) of 5c as a bright yellow solid.   
1H NMR (400 MHz, CDCl3) δ 1.56 (s, 6H, geminal CH3), 2.17 (s, 3H, CH3), 2.22 (s, 3H, CH3), 
2.78 (s, 4H, CH2), 3.25 (s, 2H, CH2).  13C NMR (100.61 MHz, CDCl3) δ 14.5, 16.9, 25.5, 29.5, 
40.1, 44.1, 136.4, 141.6, 144.5, 149.7, 167.4, 168.8, 181.8, 184.6.  HRMS (ESI) m/z [M+H]+, 
calcd = 412.0396 (calcd for C17H19BrNO6), obsd = 412.0401, –1.1 ppm error. 
(5a).  From starting material, 4a.  Purified on a 70 g/150 mL Flash Si II column (~45:1) using the 
FlashMaster chromatography system with dichloromethane/ethyl acetate (9:1). (As an alternative 
to column chromatography, crude 5a can be recrystallized from ethyl acetate/hexanes).  Yield 
61%.  1H NMR (400 MHz, CDCl3) δ 1.55 (s, 6H, geminal CH3), 1.99 (s, 3H, CH3), 2.21 (s, 3H, 
CH3), 2.79 (s, 4H, CH2), 3.29 (s, 2H, CH2), 6.50 (s, 1H, CH).  13C NMR (100.61 MHz, CDCl3) δ 
14.4, 15.6, 25.6, 29.6, 39.4, 44.2, 135.0, 141.7, 143.9, 148.7, 167.6, 168.9, 188.2, 189.2.  HRMS 
(ESI) m/z [M+Na]+ calcd = 356.1104 (calcd for C17H19NNaO6), obsd = 356.1105, –0.3 ppm 
error. 
(5b).  From starting material, 4b.  Recrystallized from ethyl acetate/hexanes.  Yield 82%.  1H 
NMR (400 MHz, CDCl3) δ 1.53 (s, 6H, geminal CH3), 1.96 (s, 3H, CH3), 2.18 (s, 3H, CH3), 2.78 
(s, 4H, CH2), 3.29 (s, 2H, CH2).  13C NMR (100.61 MHz, CDCl3) δ 12.3, 12.7, 14.4, 25.7, 29.3, 
44.3, 138.9, 140.5, 143.0, 150.1, 167.8, 169.0, 187.5, 190.4.  HRMS (ESI) m/z [M+Na]+, calcd = 
370.1261 (calcd for C18H21NNaO6), obsd = 370.1262, –0.3 ppm error. 
(5d).  From starting material, 4f.  Purified on a 70 g/150 mL Flash Si II column (~270:1) using 
the FlashMaster chromatography system with dichloromethane/ethyl acetate (14:1).  Yield 63%.  
1H NMR (400 MHz, CDCl3) δ 0.96 (t, 3H, CH3), 1.52 (s, 6H, geminal CH3), 1.61 (m, 2H, CH2), 
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2.03 (s, 3H, CH3), 2.22 (s, 3H, CH3), 2.79 (s, 4H, CH2), 3.25 (s, 2H, CH2), 3.38 (q, 2H, CH2), 
5.24 (t, 1H, NH).  13C NMR (100.61 MHz, CDCl3) δ 10.6, 11.2, 15.2, 24.0, 25.6, 29.2, 38.5, 
44.0, 47.0, 107.3, 144.3, 144.8, 145.9, 167.6, 169.0, 185.6, 187.0.  HRMS (ESI) m/z [M+H]+, 
calcd = 391.1870 (calcd for C20H27N2O6), obsd = 391.1847, 6.0 ppm error. 
General procedure for quinone–dioleoylphosphatidylethanolamine lipids 6a–d:1 
(6a).  In a typical procedure, triethylamine (78.1 mg, 0.77 mmol) and then 5a (54.6 mg, 0.164 
mmol) were added to a cooled solution (0 °C) of dioleoylphosphatidylethanolamine (115 mg, 
0.154 mmol) in 5 mL of dry DCM under argon.  The reaction was stirred for 4–6 h and allowed 
to gradually warm to room temperature.  The reaction mixture was diluted with DCM to 50 mL, 
then extracted with 5% NaHCO3 (1 × 50 mL).  The organic layer was dried with Na2SO4, and the 
solvent was removed with the aid of a rotary evaporator.  The crude residue was loaded onto a 10 
g/25 mL Flash Si II column (~50:1) using the FlashMaster chromatography system and eluted 
via a gradient of 1:1 DCM/ethyl acetate (to elute any unreacted 5a, if any) followed by 3:1:2 
DCM/MeOH/hexanes (to elute the pure product).  The combined fractions were evaporated to 
dryness and dried under high vacuum (for at least 1 h) to afford 0.122 g (82%) of 6a as a bright 
yellow wax.  1H NMR (400 MHz, CDCl3) δ 0.88 (t, 6H, CH3), 1.27 (m, 40H, CH2), 1.41 (s, 6H, 
geminal CH3), 1.57 (m, 4H, CH2), 1.99 (q, 8H, CH2), 2.01 (d, 3H, CH3), 2.15 (s, 3H, CH3), 2.29 
(t, 4H, CH2), 2.89 (s, 2H, CH2), 3.37 (d, 2H, CH2), 3.84 (d, 2H, CH2), 3.95 (d, 2H, CH2), 4.13 (t, 
1H, H–CH), 4.40 (t, 1H, H–CH), 5.26 (m, 1H, CH), 5.34 (m, 4H, CH), 6.56 (s, 1H, CH).  13C 
NMR (100.61 MHz, CDCl3) δ 14.1, 14.4, 15.6, 22.7, 24.8, 24.9, 27.2, 29.0, 29.2, 29.3, 29.5, 
29.8, 31.9, 34.1, 34.2, 38.4, 39.8, 48.8, 62.9, 63.7, 64.8, 70.4, 129.6, 130.0, 135.2, 138.9, 143.6, 
152.9, 172.8, 173.5, 173.8, 188.0, 190.5.  HRMS (ESI) m/z [M−Na]−, calcd = 960.6335 (calcd 
for C54H91NO11P–), obsd = 960.6352, –1.8 ppm error. 
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(6b).  From starting material, 5b.  Purified using identical procedure as 6a.  Yield 96%.  1H 
NMR (400 MHz, CDCl3) δ 0.88 (t, 6H, CH3), 1.27 (m, 40H, CH2), 1.37 (s, 6H, geminal CH3), 
1.57 (m, 4H, CH2), 1.94 (s, 6H, CH3), 2.00 (q, 8H, CH2), 2.10 (s, 3H, CH3), 2.29 (t, 4H, CH2), 
2.84 (s, 2H, CH2), 3.38 (d, 2H, CH2), 3.85 (d, 2H, CH2), 3.93 (t, 2H, CH2), 4.16 (t, 1H, H–CH), 
4.42 (t, 1H, H–CH), 5.28 (m, 1H, CH), 5.34 (m, 4H, CH).  13C NMR (100.61 MHz, CDCl3) δ 
12.3, 12.9, 14.3, 22.9, 25.1, 27.4, 28.8, 29.5, 29.7, 30.0, 32.1, 34.3, 34.5, 38.1, 39.8, 48.7, 63.1, 
63.8, 65.2, 70.7, 129.8, 130.2, 137.5, 138.0, 143.7, 154.0, 172.9, 173.9, 174.2, 187.6, 191.5.  
HRMS (ESI) m/z [M−Na]−, calcd = 974.6492 (calcd for C55H93NO11P–), obsd = 974.6485, 0.7 
ppm error. 
(6c).  From starting material, 5c.  Purified using identical procedure as 6a, except that a reddish-
brown (slightly more nonpolar) impurity was removed from the head of the product plug with 
the second eluent.  Yield 38%.  1H NMR (400 MHz, CDCl3) δ 0.87 (t, 6H, CH3), 1.27 (m, 40H, 
CH2), 1.40 (s, 6H, CH3), 1.58 (m, 4H, CH2), 1.99 (q, 8H, CH2), 2.14 (s, 6H, CH3), 2.29 (t, 4H, 
CH2), 2.87 (s, 2H, CH2), 3.39 (d, 2H, CH2), 3.88 (d, 2H, CH2), 3.96 (t, 2H, CH2), 4.17 (t, 1H, H–
CH), 4.41 (t, 1H, H–CH), 5.33 (m, 1H, CH), 5.33 (m, 4H, CH), 7.36 (bs, 1H, NH).  13C NMR 
(100.61 MHz, CDCl3) δ 14.1, 14.4, 16.6, 22.7, 24.9, 27.2, 28.5, 29.2, 29.3, 29.6, 29.8, 31.9, 34.1, 
34.3, 36.0, 38.7, 39.8, 48.5, 63.0, 63.7, 64.7, 70.5, 129.0, 130.0, 136.6, 137.5, 143.4, 154.7, 
172.6, 173.6, 173.8, 182.6, 184.6.  HRMS (ESI) m/z [M−Na]−, calcd = 1038.5440 (calcd for 
C54H90BrNO11P–), obsd = 1038.5453, –1.3 ppm error. 
(6d).  From starting material, 5d.  Purified using identical procedure as 6a.  Yield 77%.  1H 
NMR (400 MHz, CDCl3) δ 0.88 (t, 6H, CH3), 0.93 (t, 3H, CH3), 1.28 (m, 40H, CH2), 1.39 (s, 6H, 
geminal CH3), 1.58 (m, 2H, CH2), 1.58 (m, 4H, CH2), 1.71 (s, 6H, CH3), 2.00 (q, 8H, CH2), 2.29 
(t, 4H, CH2), 2.79 (s, 2H, CH2), 3.34 (q, 2H, CH2), 3.34 (d, 2H, CH2), 3.82 (d, 2H, CH2), 3.93 (t, 
2H, CH2), 4.14 (t, 1H, H–CH), 4.40 (t, 1H, H–CH), 5.27 (m, 1H, CH), 5.34 (m, 4H, CH).  13C 
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NMR (100.61 MHz, CDCl3) δ 8.5, 10.4, 11.2, 14.1, 15.0, 22.7, 24.2, 24.9, 25.0, 27.2, 29.2, 29.3, 
29.5, 29.8, 31.9, 34.1, 34.2, 37.9, 39.8, 45.6, 46.8, 48.5, 53.4, 62.8, 63.7, 64.8, 70.4, 106.8, 129.6, 
130.0, 140.6, 147.3, 148.4, 172.4, 173.3, 173.6, 185.8.  HRMS (ESI) m/z [M−Na]−, calcd = 
1017.6914 (calcd for C57H98N2O11P–), obsd = 1017.6910, 0.4 ppm error. 
(7).10  4-aminobenzyl alcohol (1.6 g, 12.90 mmol) and 5b (1.0 g, 2.88 mmol) were combined in a 
3-neck round bottom flask and subjected to high vacuum for 40 mins.  The flask was then purged 
with argon gas, and 6 mL of dry THF was added via syringe.  The reaction was stirred at room 
temperature under argon and in the dark.  After 3 days, the reaction mixture was diluted with 
EtOAc (400 mL) and washed with water (6 × 200 mL) until most of the excess 4-aminobenzyl 
alcohol was removed, as monitored by TLC of the organic layers (eluent = 2:1 DCM/EtOAc).  
The organic layers were combined, dried with MgSO4, and then evaporated with the aid of a 
rotarty evaporator.  Recrystallization of the crude material from DCM/EtOAc afforded 0.689 g 
(66 %) of 7 as a yellow solid.  1H NMR (400 MHz, CDCl3) δ 1.50 (s, 6H, geminal CH3), 1.95 (s, 
3H, CH3), 1.96 (s, 3H, CH3), 2.16 (s, 3H, CH3), 3.03 (s, 2H, CH2), 4.64 (s, 2H, CH2), 7.08 (s, 1H, 
NH), 7.29 (d, 2H, CH), 7.40 (d, 2H, CH).  13C NMR (100.61 MHz, CDCl3) δ 12.2, 12.7, 14.2, 
29.2, 38.4, 50.4, 64.9, 119.9, 127.8, 136.8, 137.1, 138.3, 138.4, 143.2, 152.9, 170.2, 187.5, 191.6.  
HRMS (ESI) m/z [M+H]+, calcd = 356.1863 (calcd for C21H26NO4), obsd = 356.1864, –0.2 ppm 
error. 
(8).11-12  Compound 7 (0.1 g, 0.28 mmol) was put into a 50 mL 3-neck round bottom flask and 
subjected to high vacuum for 30 mins.  The flask was then purged with argon gas, and 5 mL of 
dry THF was added with stirring.  4-nitrophenyl chloroformate (0.074 g, 0.37 mmol)  and then 
dry pyridine (0.029 g, 0.37 mmol) were added to the flask, and the reaction continued to stir at 
room temperature for 18 h in the dark.  The reaction mixture was vacuum filtered to remove the 
precipitate and then concentrated using a rotary evaporator to yield a yellow residue.  The crude 
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material had to be chromatographed on three different columns.  Column (1): 50 g/150 mL Flash 
Si II using 60:1 DCM/MeOH.  Column (2): 25 g/150 mL Flash Si II using 60:1 DCM/MeOH.  
Column (3): 10 g/25 mL Flash Si II using 100:1 DCM/MeOH.  After each column, fractions 
containing a reasonable amount of the product (Rf = 0.3, yellowish brown) were combined and 
purified using the next column to eventually remove all of the impurities.  The final fractions 
were then combined and concentrated using a rotary evaporator to yield ~94 mg (64%) of 8.  1H 
NMR (400 MHz, CDCl3) δ 1.50 (s, 6H, geminal CH3), 1.92 (s, 3H, CH3), 1.94 (s, 3H, CH3), 2.16 
(s, 3H, CH3), 3.07, (s, 2H, CH2), 5.22 (s, 2H, CH2), 7.36 (d, 4H, CH), 7.44 (d, 2H, CH), 8.26 (d, 
2H, CH).  13C NMR (100.61 MHz, CDCl3) δ 12.2, 12.7, 14.2, 29.1, 38.4, 50.4, 70.6, 119.9, 
121.8, 125.3, 129.7, 129.9, 138.3, 138.4, 143.2, 145.4, 152.4, 152.8, 155.5, 170.5, 187.5, 191.5.  
HRMS (ESI) m/z [M+H]+, calcd = 521.1925 (calcd for C28H29N2O8), obsd = 521.1907, 3.5 ppm 
error. 
(9).13  4b (0.4 g, 1.60 mmol) was dissolved in 110 mL dry DCM, to which was added N-
methylmorpholine (0.5 g, 4.79 mmol).  The mixture was cooled to –55 °C in a dry ice–2-
propanol bath.  Isobutyl chloroformate (0.26 g, 1.92 mmol) was then added, followed by addition 
of N-methylaniline (0.5 g, 4.79 mmol) after 10 mins.  The reaction mixture was stirred for 1 hr in 
the dark.  After which, the reaction was allowed to warm to room temperature with the aid of a 
water bath and then evaporated on a rotary evaporator.  The resulting dark orange solid residue 
was taken up in 70 mL of chloroform and washed with water (100 mL), 5% HCl (100 mL), 5% 
NaHCO3 (100 mL), and brine (100 mL).  The organic layer was dried over MgSO4, and the 
solvent was evaporated to yield a yellow residue.  The crude material was loaded onto a 70 g/150 
mL Flash Si II column and purified using the FlashMaster chromatography system with 
ether/hexanes (2:5).  The main yellow plug that eluted with an Rf = 0.25 was collected, and the 
solvent was evaporated to yield 0.268 g (49%) of 9.  1H NMR (400 MHz, CDCl3) δ 1.29 (s, 6H, 
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geminal CH3), 1.96 (s, 3H, CH3), 2.00 (s, 3H, CH3), 2.09 (s, 3H, CH3), 2.73 (s, 2H, CH2), 3.15 (s, 
3H, NCH3), 7.19 (d, 2H, CH), 7.35 (t, 1H, CH), 7.44 (t, 2H, CH).  13C NMR (100.61 MHz, 
CDCl3) δ 12.1, 12.7, 14.1, 28.4, 37.1, 38.0, 47.6, 127.5, 127.8, 129.8, 136.2, 137.7, 143.6, 144.0, 
154.8, 172.1, 187.7, 191.2.  HRMS (ESI) m/z [M+H]+, calcd = 340.1913 (calcd for C21H26NO3), 
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methylated version of 7, because the latter could not be synthesized in sufficient quantities with 
acceptable purity.   
The 1H NMR spectra of 9 showed no change after 24 hours (Figure 2.3), particularly in 
the region between 0–3 ppm, so it was concluded that 9 is stable in 70% DMSO-d6/30% D2O.  
Thus, it was found that methylation of the aromatic amine, indeed, inhibited formation of the 
spirolactam in aqueous solution.     
2.3 Summary 
 
 The variously substituted simple quinones (1a–h) and quinone propionic acids (4a–h) 
were synthesized and characterized for subsequent cyclic voltammetry studies (see Chapter 3).  
The 4 target Q-DOPE lipids (6a–d) and their respective quinone succinimide propionate 
intermediates (5a–d) were synthesized and characterized.  The Q-DOPE lipids were prepared 
into liposomes for encapsulation and triggered release studies (see Chapter 4).  Quinone 
compounds 7 and 8 were synthesized and characterized with the intent of coupling DOPE to 8 
through the carbonate carbon (eliminating 4-nitrophenol), to generate a self-immolative spacer 
between the quinone and DOPE.  Once prepared into PEGylated liposomes, the purpose of an 
appropriate self-immolative spacer will be to extend the quinone trigger moiety away from the 
bilayer surface, comparable to the PEG chains, thus possibly improving accessibility of NQO1 to 
the quinone substrate.  However, it was found that 7 undergoes rapid cyclization to form a 
spirolactam in aqueous media, as evidenced by 1H NMR specroscopy, which defeats the purpose 
of the extended spacer.  To confirm the findings of Nicolaou et al.,13 9 was synthesized and its 
stability investigated by 1H NMR in aqueous media, revealing that methylation of the aromatic 
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EVALUATION OF SIMPLE QUINONES AND QUINONE PROPIONIC ACIDS USING 
CYCLIC VOLTAMMETRY AND X-RAY CRYSTALLOGRAPHY 
3.1 Introduction 
 Chemical groups that are triggered by a variety of stimuli and can be used to initiate the 
destruction or creation of active species, such as volatiles,1 prodrugs2-4 and biologicals,5-6 or 
molecular assemblies—including dendrimers,7-10 polymeric micelles,11-12 and liposomes13-15—
are crucial to a variety of applications, including diagnostics, drug delivery, and sensing.  
Exogenous (e.g. light/radiation,14,16 hyperthermia14,17) and endogenous (e.g. low pH14,18-19 and 
enzymes14,20-21) stimuli are typically used to activate trigger groups.  In particular, for diagnostics 
and drug delivery, endogenous stimuli can offer high specificities (Km) and sensitivities (Vmax, 
enzyme turnover rate), if appropriate trigger groups exist so as to take full advantage of diseased 
site characteristics. 
 In the case of enzymatically-activated trigger groups, high specificity and sensitivity of 
trigger group removal/modification should be possible by tuning the molecular structure of the 
trigger group.2,22  Our immediate interest was in building a collection of quinone-based 
trimethyl-lock23 cyclization groups that undergo cyclization/target release upon triggered 
reduction by chemical agents13 and NAD(P)H:quinone oxidoreductase type 1 (NQO1),24 an 
enzyme that is upregulated in numerous cancer cell lines and tumors.25  The specificity and 
sensitivity of quinone trigger group removal is hypothesized to be a function of the rate of 
reduction/cyclization and dependent upon the reduction potential of the quinone to hydroquinone 
process.  Knowledge about these quinone trigger groups will broaden the scope and capabilities 
of enzyme-initiated liposome contents delivery,14 latent fluorophore imaging,26 and reagent 
delivery in microfluidic devices.27 
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 To that end, the specific aim was to tune the reduction potential of quinone triggers by 
substitution on the quinone ring without disturbing the geometry of the trimethyl lock.  With 
these tunable quinone triggers in hand, we should be able to make highly sensitive the human 
NQO1 reduction of the quinone and also avoid non-specific quinone reduction by other 
adventitious reducing agents present in vivo.  
 In order to more fully define the utility of quinone trigger groups in development of 
enzyme-based prodrugs3 or redox-responsive macromolecular/supramolecular (e.g. dendritic7-8 
and liposomal13) delivery and imaging26 systems, we determined the quinone trigger group 
reduction potentials from linear-sweep voltammetry in buffered aqueous, near-physiological pH 
solutions.  By careful selection of the quinone trigger group, it should be possible to program the 
reduction sensitivity and specificity of responsive assemblies and prodrugs.  For example,  the  
reduction  potential  of  the  FAD  center of rat NQO1 is −0.159 V vs. standard hydrogen 
electrode (SHE);1 although the rate of select substrate reduction by human NQO1 is 2–5 times 
slower than that of the rat variant,1 we anticipated that the rate of quinone reduction by human 
NQO1 will, in general, increase with increasingly positive reduction potential.  In addition, it is 
important to tune the reduction potential of the quinone-based triggers so as to decrease or 
prevent their non-specific reaction with adventitious reducing agents present in a given 
application environment, such as glutathione (−0.22 V vs. SHE)1 or ascorbate (0.051 vs. SHE).2  
3.2 Experimental Section 
3.2.1 Materials and Methods 
 Synthetic protocols of the simple quinones (1a–h) and quinone propionic acids (4a–h) 
used in cyclic voltammetry (CV) experiments and characterized by X-ray crystallography are 
described in Chapter 2.  CV experiments were performed by Maria Fabiana Mendoza (colleague) 
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 Perhaps the most intriguing result in the trimethyl lock series (Y = R3 = Me; 4a–b, 4e–h) 
was the unexpectedly high reduction potential of the dimethoxy species 4h; a similar result was 
obtained for the simple dimethoxy-quinone 1h.  We anticipated that 1h and 4h would have very 
negative reduction potentials due to resonance effects from both methoxy groups.  However, it 
has been shown that steric interactions between adjacent methoxy substituents on quinones result 
in one methoxy group being out of plane, thereby inhibiting the full resonance effect.29-32  
Consequently, the dominating force of the out-of-plane methoxy oxygen in 1h and 4h was 
inductive. 
 The quinone reduction potential was found to be more negative by roughly 0.2–0.3 V 
when the trimethyl-lock motif was present for structurally similar compounds.  For example, 
comparison of 4a and 1c led to an observed −0.19 V difference, while it was −0.34 V for 4b vs. 
1d, −0.20 V for 4e vs. 1f, −0.18 V for 4g vs. 1g, and −0.28 V for 4h compared to 1h.  From these 
results, we hypothesized that the trimethyl-lock motif affects the planarity of the quinone ring 
such that there exists a more localized quinone π-system that is, in general, more difficult to 
reduce than its non-trimethyl-locked counterpart. 
3.3.2 X-ray Crystallographic Analysis of Quinones 
 Although the conformation(s) of the quinone propionic acids is/are different in solution, 
X-ray crystallographic analyses of trimethyl-locked quinone propionic acids of high crystal 
quality (4a, 4b, and 4e) were conducted (Table 3.2) in order to approximate the effect of the 
trimethyl lock on the planarity of the quinone ring,.  For ease of following assigned geometric 
parameters, see Figure 3.7 for letter designations of each atom in the substituted trimethyl-locked 
propionic acids.  In a planar system, torsion angles a–b–c–d and a–f–e–d should be ~0°; 
however, the latter torsion angle for compounds 4a (R1 = H), 4b (R1 = CH3), and 4e (R1 = Br) 
significantly deviated from planarity by 21.1°, 23.4°, and 18.49°—all very similar, comparable 
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values between these compounds.  This non-planarity resulted from the strain imposed on the 
quinone ring by the trimethyl lock, thus restricting conformational freedom of the propionic side 
chain and forcing it to bend back around toward the g–a carbonyl.  In turn, this caused the 
carbonyl adjacent to the trimethyl lock to be pushed out of plane, as noted by the g–a–b–c and g–
a–f–e torsion angles of 4a, 4b, and 4e that deviated from the ideal 180° by ~22–38°.  Thus, the 
presence of the trimethyl-lock moiety led to “warped” quinone systems that were more difficult 
to reduce by 0.2–0.3 V than their non-trimethyl-locked analogues. 
Table 3.2.  Torsion angles (°) from X-ray crystallography dataa for quinone propionic acids. 




(°) 4a 4b 4e 4c 4d 
g–a–b–c 
180° 
−157.25 (10) −158.16 (13) −151.43 (11) −177.44 (10) 178.28 (13) 
g–a–f–e 146.25 (9) 145.00 (13) 142.43 (10) 175.86 (10) −178.12 (12)
a–b–c–d 
0° 
0.54 (14) 2.1 (2) −0.44 (15) 1.40 (15) −0.2 (2) 
a–f–e–d 21.10 (12) 23.40 (18) 18.49 (14) 1.64 (15) −0.09 (18) 
i–d–c–b 
180° 
174.63 (9) 175.54 (13) 170.24 (10) 176.83 (10) −179.06 (13)
i–d–e–f 173.55 (9) 170.56 (13) 180.00 (10) −178.44 (10) 179.22 (12) 
aParameters were determined from CIF data using CrystMol software.  Estimated standard 
deviations are given in parentheses next to each calculated value.  bRefer to Figure 3.7 for letter 
designations of bond sequences.  cIdeal torsion angles were adapted from Wang et al.33 
 
 It is significant to note that there did not appear to be a correlation between the identity of 
the R1-substituent (–H, –Me, –Br) and the trimethyl-lock-induced structural changes, as the 
results were all similar between these compounds.  Thus, we concluded that the observed 
differences in reduction potential for 4a–b and 4e–h were due to electronic effects imparted  
by R1.  This tunability has important implications with regard to the specificity and sensitivity of 





Figure 3.7.  Letter designations for each atom in the quinone propionic acids. 
 
 By contrast, the torsion angles for compounds 4c and 4d, which do not contain the TML, 
were more on par with the ideal values (Table 3.2).  The torsion angles g–a–b–c and g–a–f–e for 
these two compounds only deviated by 3.35° and 1.80°, respectively, from the ideal 180°.  The 
planarity of both the quinone ring and the g–a carbonyl remained intact without the TML to 
impose significant strain on the system. 
 The “near-attacking conformation” (NAC) as described by Lightstone and Bruice34, and 
then again by Wang et al.,33 is also important to our TML-catalyzed cyclization process.  The 
directionality and distance of the nucleophilic oxygen (g) to the carbonyl carbon (o) of the 
propionic acid is critical for the NAC and efficient cyclization to form the lactone.  Angle g–o–p 
in Table 3.3 best describes the relative directionality of the relevant atoms prior to reduction, 
which ideally should be about 90°.33  The presence of the TML in compounds 4a, 4b, and 4c 
clearly promoted formation of the NAC by reducing the number of unproductive conformers and 
bringing the angle within about 3° of the ideal 90° for each.  By contrast, compounds 4c and 4d 
(no TML) deviated by about 19° and 14°, respectively.  Angle a–g–o describes the relative 
directionality after reduction of the quinone to the hydroquinone, which ideally should be about 
90–120°.33-34  With the exception of 4d, all of the compounds deviated from the ideal by at least 
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10°, regardless of the presence or absence of the TML.  Wang et al. also observed deviations of 
about the same magnitude but concluded that these deviations were relatively small given the 
dynamic motions of molecules in solution.33  There was no apparent reason for 4d’s exception to 
this trend; however, its relatively good directionality was thwarted by the long distance (4.549 Å) 
between the attacking oxygen (g) and the electrophilic carbon (o). 
Table 3.3.  Intramolecular reaction angles (°) and distances (Å) from X-ray crystallography dataa 
for quinone propionic acids. 
 quinone propionic acids 
angleb (°) idealc (°) 4a 4b 4e 4c 4d 
a–g–o 90–120° 76.5 (1) 73.9 (1) 78.1 (1) 77.7 (1) 88.5 (1) 
g–o–p ~90° 93.3 (1) 93.0 (1) 86.7 (1) 70.6 (1) 103.7 (1) 
distanceb (Å) idealc (°) 4a 4b 4e 4c 4d 
g–o ≤3.2 Å 3.046 (1) 3.187 (2) 2.966 (1) 3.705 (1) 4.549 (2) 
l–m 2.538 Å 2.541 (1) 2.531 (2) 2.546 (2) 2.493 (1) n/a 
aParameters were determined from CIF data using CrystMol Software.  Estimated standard 
deviations are given in parentheses next to each calculated value.  bRefer to Figure 3.7 for letter 
designation of bond sequences.  cIdeal angles and distances were adapted from Wang et al.33 
 
 A non-bonded distance of less than or equal to 3.2 Å between the oxygen (g) and the 
carbon(o) is also needed for the near-attacking conformation.34  The TML-containing compounds 
4a, 4b, and 4e all possessed g–o distances commensurate with the ideal.  As expected, 
TML-lacking compounds, 4c and 4d, did not have adequate g–o distances to meet the criteria of 
a NAC.  The non-bonded l–m distances between the geminal methyl carbons for the 
TML-containing compounds (4a, 4b, 4e) also fit the ideal 2.538 Å, which is observed for 







3.4 Conclusions  
 
 In summary, we have developed a family of redox-responsive intramolecular cyclization 
groups whose members can be selectively and specifically triggered as a result of their chemical 
structure.  Interestingly, simple quinones and quinone propionic acids containing a halogen 
substituent (i.e. 1e–g and 4e, g) had lower reduction potentials than was anticipated, versus their 
hydrogen-counterparts, which suggested that the halogens were not as electron-withdrawing as 
expected.  The reasons for this observed result are still debated; however, it seems that the 
halogens may have been pushing more electron-density into the ring through resonance 
interactions, as reported by some germane literature findings.29  Even though X-ray 
crystallography only reveals information about chemical structure in the solid state, the results 
did give some idea about possible conformation(s) of the quinone propionic acids in solution.  
The presence of a trimethyl lock at the 6-position of the quinone propionic acid resulted in a 
general structure wherein the quinone ring was puckered or “warped” and was independent of 
the substituent at the 2- or 3-positions of the quinone ring (R1 and R2).  However, it was found 
that the R1 and R2 substituents dictated the reduction potential of the quinone trigger group, 
thereby providing a ~0.2 V range for the triggering of the cyclization process.  This range of 
reduction potentials provides access to tunable quinone trigger group activation by a human 
quinone oxidoreductase (hNQO1) known to be upregulated in a variety of cancers.35-39  
Furthermore, the tunable nature of the quinone trigger group resulted in control over non-specific 
triggering by adventitious reducing agents.  Work has been underway in our group to study the 
use of the trimethyl-locked quinone propionic acid triggers in enzyme-initiated liposome 
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ENCAPSULATION AND TRIGGERED RELEASE STUDIES OF VARIOUS Q-DOPE 
LIPOSOMES USING FLUORESCENCE SPECTROSCOPY 
 
4.1 Introduction 
 The ability of a paramedic to respond to an emergency initially depends on the 
ambulance to transport them safely to the scene; therefore, it is important for the ambulance to 
remain intact (i.e. avoid wrecks) while en route.  Likewise, maintaining the integrity and stability 
of the liposome delivery vehicle is of primary importance until the diseased site is reached.  
While the total pharmacological profile of a liposomal drug formulation is characterized by the 
adsorption, distribution, metabolism, and excretion (ADME) of both the encapsulated drug and 
the liposome excipient, the therapeutic efficacy of the drug cargo mainly depends on the 
pharmacokinetics and tissue distribution of the liposome.1 Moreover, drug bioavailability also 
depends on the total amount of drug released from the liposome carrier.2  Thus, it is important to 
understand liposome pharmacokinetics and drug pharmacodynamics such that drug release rates 
can be tailored to fit the efficacy profile of the drug cargo.1-2 
 Therapeutically-optimized drug release rates are essential for maximizing the benefits of 
liposomal drug formulations.1  As a case-in-point, Johnston et al. showed that moderate release 
rates were more efficacious for liposomal formulations that contained cell cycle-specific drugs, 
such as vincristine.2-3  With prolonged exposure to cells, vincristine has been shown to cause 
greater cell death in vitro and have increased antitumor activity in vivo.3-9  Therefore, optimizing 
drug release rates from liposome carriers is an important aspect in order to fully exploit the 
therapeutic effect of the carried drug.  To this end, it is important to understand how a liposome 
excipient destabilizes and releases it cargo.  Moreover, inclusion of a responsive element into the 
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liposome bilayer provides a way to control the permeability of the membrane and, thus, the rate 
of contents release.1   
 On a related topic, enzymatically-triggered liposome delivery systems also require 
optimum conditions in order to achieve site-specific drug release—that is, specificity of the 
targeted enzyme and the substrate (a component of the liposome) must be ideal such that drug 
delivery is triggered only by that enzyme.  To date, the two main enzymes studied to initiate 
liposomal drug release extracellularly are secretory phospholipase A2 type IIA (sPLA2–IIA) and 
matrix metalloproteinase–2 and –9 (MMP–2 and MMP–9), which represent the opposite ends of 
the spectrum in terms of substrate specificity.   
 sPLA2–IIA catalyzes the hydrolysis of the sn–2 ester bond in glycerophospholipids, 
particularly those that are in an aggregated form (e.g. liposomes and micelles) and possess a net 
anionic charge.10-13  Neutral membranes composed of zwitterionic lipids, such as 
phosphocholines, induce virtually no enzymatic action from sPLA2–IIA.11-13  While the topology 
of the membrane surface (i.e. lipid composition, morphology/arrangement, membrane charge) 
with which sPLA2–IIA acts is important to the activity of this enzyme,11-12,14 its substrate 
specificity is still more general compared to that of MMP–2 and MMP–9.      
 Specialized lipopeptides containing the amino acid substrate sequence, 
L-prolyl-L-leucyl-glycyl-L-leucine (AcProLeuGlyLeu), are required for MMP-triggered liposome 
destabilization.2,15  In fact, Kline et al. found that both MMP–2 and MMP–9 are highly sensitive 
to the structure and orientation of certain AcProLeuGlyLeu residues.15  Strong hydrogen bonds 
in the active sites of these MMPs are responsible for their increased substrate specificity.15  
Small changes or deviations in the molecular composition of the amino acid substrate sequence 
result in loss of interaction with MMP–2 and/or MMP–9.15    
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 The quinone trigger, used in the redox-active liposome delivery vehicles described 
herein, provides a measure of tunability that is bipartite: (1) the stimuli-responsive 
destabilization behavior and (2) the enzymatic selectivity can both be adjusted according to 
different functionalities present on the quinone ring.  In this way, release rates of entrapped cargo 
can be optimized, and enhanced selectivity for the targeted enzyme can be achieved.  The 
additional degree of tunability that these liposomes offer makes possible the realization of a 
moderately sensitive enzymatically-triggered system via quinone electronics, as opposed to 
liposomes activated by sPLA2–IIA (not very substrate specific) or MMP–2 and –9 (very 
substrate specific). 
4.2 Experimental Section 
4.2.1 Molar Extinction Coefficient Determination 
 To determine the molar extinction coefficients (ε) of the Q-DOPE lipids, ca. 1–3 mg of 
the lipid were dissolved in 10–25 mL of chloroform to make the stock solution.  A serial dilution 
of the stock solution yielded concentrations that ranged from ca. 0.015–0.12 mM.  The 
absorbance values of these dilutions were obtained spectrophotometrically using a Varian Cary 
50 Bio UV-Visible Spectrophotometer and then plotted versus concentration.  The slopes of each 
graph were multiplied times 103 to yield the ε (in M−1 cm−1) for each Q-DOPE lipid. 
 To determine the molar extinction coefficients of the Q-DOPE liposomes, the lipids had 
to first be prepared into empty (no encapsulated calcein) liposomes (see 4.2.2 below), except ca. 
2–5 mg of the lipid were dissolved in buffer at a concentration of 1 mg mL−1.  Then, this solution 
was diluted 10-fold to generate the stock solution, from which serial dilutions were made that 
ranged from ca. 0.016–0.10 mM.  The absorbance values of these dilutions were obtained 
spectrophotometrically, as described above, and the ε for each Q-DOPE liposome was extracted 
from the absorbance versus concentration plots. 
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4.2.2 Liposome Preparation16   
 Liposomes were prepared according to the “lipid thin-film and extrusion” method,17-18 as 
previously reported by our group.16  Q-DOPE lipid (1–3 mg) was dissolved in chloroform (2–3 
mL) in a 25-mL round-bottom flask, and the lipid solution was evaporated to a thin lipid film 
using a stream of argon gas.  The films were dried under high vacuum for 1 h and redissolved in 
pH 7.4, 50 mM phosphate buffer/75 mM KCl at a concentration of 1 mg mL−1.  The solution was 
aged (1 h) with occasional vortexing (ca. 15–30 s at 20 min intervals), after which it underwent 6 
freeze-thaw cycles using a dry ice/acetone bath, followed by extrusion (14 times) at ambient 
temperature through a 100-nm pore Whatman Nuclepore polycarbonate track-etched membrane 
using an Avanti Mini-Extruder (Avanti Polar Lipids, Alabaster, Alabama).  For the preparation 
of calcein-loaded liposomes, the entire “extrusion” procedure described above was used, except 
that the buffered solvent also contained dissolved calcein (40 mM, Sigma-Aldrich, Milwaukee, 
WI).  Following extrusion, the nonencapsulated dye was separated from the 
liposome-encapsulated dye by gel filtration of the extruded solution through a column of 
Sephadex G-75 resin (GE Healthcare BioSciences, Piscataway, NJ).  Separate gel-filtration 
columns were used for each individual Q-DOPE liposome composition: to decrease non-specific 
adsorption, non-calcein-encapsulated liposomes were passed through the columns prior to their 
initial use. 
4.2.3 Calcein Release Experiments16   
 The purified calcein-loaded liposomes were diluted with buffer to achieve an arbitrary 
concentration that was based on the absorbance (Varian Cary 50 Bio UV-Visible 
Spectrophotometer) of the encapsulated calcein at 487 nm, typically maintained between  
0.08–0.1; Absorbance values for the liposome-encapsulated calcein were kept ≤ 0.1 to avoid 
saturation of the detector after calcein release.  Then, 3 mL of this diluted solution were put into 
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a 4-sided transparent quartz cuvette and degassed for a few min.  Fluorescence intensities  
(λex = 490 nm, λem = 515 nm) were recorded using a Perkin-Elmer LS 55 Fluorescence 
Spectrometer with a PTP-1 Fluorescence Peltier System and PCB 1500 Water Peltier System.  
Excitation and emission slit widths were set to 5.0 nm each.  Baseline fluorescence (desired 
relative intensity < 350 to avoid saturation of detector upon dithionite addition) was obtained for 
0.5–1 hr to monitor the stability of liposomes in solution.  A degassed solution of ca. 2.5–3.0 mg 
of Na2S2O4 (85%, Sigma-Aldrich) in 1 mL of buffer was prepared and an appropriate aliquot 
(normally, 17–21 µL) was injected into the cuvette to attain 0.3 mmol of added Na2S2O4.  After 
injection, the cuvette was vigorously shaken, and the initial “trigger” time was noted.  Data was 
collected for 0.10 s at 1 min intervals over a maximum 25-hour period of time.  To stop the 
experiment, and establish 100% calcein release, 15 µL of a 15% (w/v) Triton X-100 (Sigma-
Aldrich) solution was added to the cuvette, and data collection continued for an additional 10 
min. 
4.2.4 Liposome Characterization16   
 Dynamic light scattering measurements were obtained from backscatter intensities (173°, 
633 nm red laser) obtained at 25 °C with calcein-free liposomes using a Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, U.K.) particle size analyzer; DLS intensity distributions 
of calcein-encapsulated liposomes were previously found to be indistinguishable from those of 
the calcein-free liposomes.16  Zeta potentials of calcein-free liposomes were obtained using the 
same Zetasizer Nano ZS instrument with closed, folded capillary zeta potential cells. 
4.3 Results and Discussion 
4.3.1 Molar Extinction Coefficients of Q-DOPE Liposomes 
 Originally, the purpose of determining the molar extinction coefficient (ε) of each 
Q-DOPE liposome was to calculate the concentration of the liposome samples in the calcein 
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release experiments.  If this method for determining the liposome concentration was accurate, it 
could be used to adjust the amount of sodium dithionite added to the liposome samples such that 
desired molar ratios of dithionite-to-lipid could be achieved.  The absorbance values recorded 
and used to generate the dilution curves correspond to the π–π* transition of the quinone.  
Because the effective, local concentration of quinone in liposomal form (versus as individual 
Q-DOPE lipids) is different due to their close proximity to each other in the bilayer, the molar 
extinction coefficient of the free Q-DOPE lipids dissolved in chloroform was also determined, as 
a form of verification.  The molar extinction coefficients of the Q-DOPE lipids and liposomes 
are given in Table 4.1.   
Table 4.1.  Molar extinction coefficients of Q-DOPE lipids and liposomes. 
 molar extinction coefficient, ε (M−1 cm−1) 
Q-DOPE composition lipidsa liposomesb 
QH–DOPE (6a) 11,200±200 11,000±200 
QMe–DOPE (6b) n.d.c 5,500d 
QBr–DOPE (6c) 9,380±30 6,560±30 
QnPrNH–DOPE (6d) 8,070±70 9,320±30 
aLipids were dissolved in chloroform.  bLiposomes were prepared in pH 7.4, 50 mM 
phosphate buffer/75 mM KCl.  cNot determined.  dDetermined by Forsythe and McCarley, 
unpublished results. 
 
 From these results, it was clear that the formulation of Q-DOPE lipids (i.e. as free lipids 
or in liposomal form) does affect their spectrophotometrically-determined molar extinction 
coefficients.  With the exception of QH–DOPE, the molar extinction coefficients of the lipids and 
the liposomes varied considerably for each Q–DOPE.  Therefore, it was concluded that this 
method is not accurate or reliable for determining the liposome concentration in the calcein 
release experiments.  (As a result, it was deemed unnecessary to determine the molar extinction 
coefficient for the QMe–DOPE lipids in chloroform.)  Instead, the concentrations of the diluted 
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liposomes were based on the absorbance of encapsulated calcein at 487–490 nm and maintained 
between absorbance values 0.08–0.1 (Table 4.2), such that the relative liposome concentration 
was approximately the same between trials. 
4.3.2 Release Behavior of Q-DOPE Liposomes 
 The purified calcein-loaded Q-DOPE liposomes were diluted so that, upon triggered 
release, the concentration of free calcein did not cause an increase in fluorescence signal high 
enough to saturate the detector.  The relative concentrations of the diluted liposome samples 
were determined based on the absorbance of the encapsulated calcein at 487–490 nm, and these 
absorbance values were maintained between 0.08–0.1 in order to keep the liposome 
concentrations relatively constant between trials (Table 4.2).  A fellow colleague had already 
conducted calcein release experiments with QMe–DOPE liposomes, so these liposomes were 
prepared and analyzed again as a “benchmark” or standard to which the other liposomes’ 
behaviors were compared and to ensure that the experimental procedure was being executed 
properly and reproducibly.   
 Upon injection of sodium dithionite (the reducing agent), the redox-active liposomes 
became destabilized and release of the entrapped calcein ensued at different rates that were 
characteristic of their individual Q-DOPE lipid composition.  In other words, each type of  
Q-DOPE liposome had its own distinct calcein release profile, which can be seen in Figure 4.1.  
Qualitatively, QMe–DOPE and QnPrNH–DOPE appeared to have similar release behaviors, while 
QH–DOPE and QBr–DOPE seemed to destabilize much differently.       
 To quantitatively compare the 4 different Q-DOPE liposomes, average lag times and 
average t50% values were determined (Table 4.3).  The “lag time” refers to the contraction event 
in which there is a decrease in fluorescence signal after injection of the reducing agent.  The lag 
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time was defined as the time elapsed between two distinct events: the initial injection of 
dithionite and the contraction maximum (i.e. the lowest fluorescence intensity reached).   
Table 4.2.  Resulting absorbance values for the final dilutions of the calcein-loaded Q-DOPE 
liposomes.  Arbitrary concentrations of the diluted liposomes were based on the absorbance of 
encapsulated calcein at 487–490 nm and maintained between 0.08–0.1.  The other absorbance 
values listed at wavelengths < 300 nm correspond to the quinone moiety and are provided for 
completeness.  Each trial corresponds to a calcein release experiment.    
 wavelength (nm), absorbance 
lipid composition of 






























aNot determined because no further trials were needed: the liposome release behaviors 
corroborated each other in the preceding trials.  
 
It has been hypothesized that the liposome surface undergoes dehydration upon cleavage of the 
quinone stabilizer from the DOPE lipid, which is a necessary step in order overcome hydration 
repulsive forces that prevent the close approach of apposing liposome bilayers and subsequent 
contact-driven rupture.19-20  As a result, this dehydration event causes a shrinkage or contraction 
of the liposomes that increases the self-quenching concentration of the calcein, thus decreasing 
the observed relative fluorescence intensity.  The QBr–DOPE liposomes had the shortest average 
lag time, while the QH–DOPE liposomes had the longest average lag time.  All of the average lag 
times were statistically different, as there was no overlap within the experimental error, and did 




Figure 4.1.  Calcein release profiles (normalized) of various Q-DOPE liposomes as determined 
by fluorescence emission spectroscopy (λex = 490 nm, λem = 515 nm).  Each trace represents the 
typical release behavior observed for each Q-DOPE liposome composition. 
 
 The “t50%” was defined as the time at which 50% of the encapsulated calcein was 
released.  It should be noted that, first, all of the trials for each Q-DOPE liposome had to be 
normalized (set to 100%) to the total amount of calcein actually released, because not every trial 
resulted in 100% calcein release—the cause of which is currently unknown.  While the reason(s) 
behind this variation in calcein release can only be speculated, it is suspected that a few different 
factors are involved.  The nature of the Q-DOPE lipid appears to have a substantial effect: the 
total percentage of calcein release (not normalized, raw data) from the QBr–DOPE and  
QH–DOPE liposomes varied the most between individual trials, while the QMe–DOPE and 
QnPrNH–DOPE liposomes consistently released close to 100% of encapsulated calcein in each 
trial.  Moreover, the more variable behavior of the QBr–DOPE and QH–DOPE liposomes was 



























evidenced by the larger standard deviations of their respective average t50% values, as compared 
to that of the more consistent QMe–DOPE and QnPrNH–DOPE liposomes.   
Table 4.3.  Average lag times and t50% of Q-DOPE liposomes. 
lipid composition of liposome average lag time (min.) average t50% (min.) 
QH–DOPE (6a) 40.3±0.6a 80.7±10.5a 
QMe–DOPE (6b) 24.0, 26.0b 35.5, 38.5b 
QBr–DOPE (6c) 13.0±0.8c 23.0±6.4c 
QnPrNH–DOPE (6d) 18.7±2.1d 32.0±2.8d 
aAverage of three trials.  bTwo trials.  cAverage of four trials.  dAverage of three trials.  Errors 
expressed as ± one standard deviation are given next to each average. 
 
4.3.3 Average Diameters and Zeta Potentials of Q-DOPE Liposomes 
 To possibly help explain the results/trends observed during the calcein release 
experiments, the Q-DOPE liposomes were characterized by dynamic light scattering, from which 
their average diameters and zeta potentials were elucidated (Table 4.4).  Again, the QMe–DOPE 
liposomes were analyzed as a standard for comparison: a colleague had already determined an 
average z-average diameter of 112.7±0.6 nm (PDI = 0.09±0.14) and average zeta potential of 
−62±4 mV for QMe–DOPE liposomes in 50 mM phosphate buffer/50 mM KCl.  These results 
compared favorably with those presented in Table 4.4 for the QMe–DOPE liposomes.  As 
expected, the Q-DOPE liposomes possessed average diameters in the 90–150 nm range, which 
was within the 80–200 nm range found for similar Q-DOPE liposomes as previously reported by 
our group.16   
 The average zeta potentials for the Q-DOPE liposomes ranged from −55 mV to −60 mV.  
All of the average zeta potentials were within the error for each liposome, except that of  
the QH–DOPE (−59±1 mV) and QnPrNH–DOPE (−55±2 mV) liposomes, whose error did not 
overlap.  The similar average zeta potential values do not seem to correlate with, or be an 
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indication of, the release behavior of these liposomes.  For example, even though the average 
zeta potentials of the QH–DOPE and QBr–DOPE liposomes are very similar, their release 
behaviors were quite different, at opposite ends of the spectrum from each other—QBr–DOPE 
liposomes released entrapped calcein the fastest, while QH–DOPE liposomes had the slowest 
release rates.     
Table 4.4.  Averagea diameters and zeta potentials of Q-DOPE liposomes.  
lipid composition of 
liposome 
average z-avg. 
diameter (nm) average PDI
b  average zeta potential (mV) 
QH–DOPE (6a) 115.6±0.2 0.06±0.01 −59±1 
QMe–DOPE (6b) 113.7±0.1 0.08±0.02 −60±3 
QBr–DOPE (6c) 131.0±0.4 0.07±0.02 −58±2 
QnPrNH–DOPE (6d) 94.7±1.1 0.09±0.01 −55±2 
aValues in each column are averages of three trials from a single preparation.  Errors expressed 




 Calcein-loaded liposomes composed of 4 different lipid compositions (QBr–DOPE,  
QH–DOPE, QMe–DOPE, and QnPrNH–DOPE) were prepared and diluted to arbitrary 
concentrations based on absorbance (0.08–0.1) of the loaded calcein at ca. 490 nm—not 
according to calculated concentrations based on their molar extinction coefficients, due to 
disagreement between the ε values determined from lipids versus liposomes.  The encapsulation 
and triggered release behaviors of these liposomes were investigated using fluorescence 
spectrometry.  Qualitative comparison of the release curves between the various liposomes 
revealed distinctly different behaviors, indicating that quinone substitution can be used to control 
the stimuli-responsive behavior of these liposomes.  Upon addition of the reducing agent,  
QBr–DOPE liposomes released the entrapped calcein the fastest, while the rate of calcein release 
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from QH–DOPE liposomes was much slower.  The relative release profiles of QMe–DOPE and 
QnPrNH–DOPE liposomes were qualitatively the most similar and exhibited comparable t50% 
values.  From the raw data, the total percentage of calcein release from QMe–DOPE and  
QnPrNH–DOPE liposomes was nearly constant, at approximately 100% for each trial.  More 
variation in the total percentage of calcein release was observed for QBr–DOPE (50–100%) and 
QH–DOPE (70–95%) liposomes between trials (data not shown).   
 The 4 different liposomes were all found to have similar average diameters in the  
90–150 nm range.  The average zeta potentials for all the liposomes were also about the  
same, ranging from −55 mV to −60 mV.  Neither the z-average diameters nor the zeta potentials 
seemed to correlate with the release behaviors of the liposomes.  The marginally more positive 
zeta potential of the QnPrNH–DOPE liposomes, compared to that of the other liposomes, indicated 
that either the n-propylamino group was not protonated or scarcely protonated such that its 
impact on the overall charge of the bilayer was minimal at best.   
 It is interesting to consider the role of the n-propylamino group in the destabilization 
process, aside from its electronic (inductive/resonance) contributions to the ring.  It has been 
becoming evident that, upon reduction of the quinone, the rate-determining step is the 
breakdown of the tetrahedral intermediate that forms as a result of the intramolecular cyclization 
event.  The nitrogen of the n-propylamino group may have been acting as an internal base to 
catalyze this step, thus, enhancing the destabilization rate (i.e. shorter average lag time and 
average t50%) of these liposomes.   
 Referring back to the electrochemical results in Chapter 3, it was also apparent that the 
reduction potentials (Ep,c) of the corresponding quinone propionic acids did not give a clear 
indication/prediction of the release behaviors of their Q-DOPE liposome counterparts.  It should 
be noted that the observed reduction potentials for the quinone propionic acids may not 
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necessarily have reflected the same trend for the corresponding Q-DOPE lipids, or liposomes for 
that matter, being chemically different entities.  Therefore, while the electrochemical properties 
of the simple quinones and quinone propionic acids provided some important information about 
the influence of quinone substitution on the reduction potentials of these compounds, the release 
behavior of the Q-DOPE liposomes cannot be predicted from these values.  
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CONCLUSIONS AND OUTLOOK 
5.1 Summary 
 The overall goal of this research was the development of redox-active liposome delivery 
agents composed of fusogenic dioleoylphosphatidylethanolamine (DOPE) stabilized with an 
electrochemically-active quinone (Q) trigger moiety whose electronic structure helps control 
liposome activation and rate of destabilization (payload delivery) upon interaction with a 
reducing stimulus.  The synthesis and evaluation of a series of water-soluble, quinone-propionic 
acids (Q-COOH) by cyclic voltammetry (CV) allowed the electrochemical properties of these 
compounds to be determined in aqueous media.  From CV measurements, it was found that 
quinone substitution with electron-donating groups displayed more negative reduction potentials; 
whereas, electron-withdrawing groups caused more positive reduction potentials, in general.  The 
electrochemical contribution of the propionic acid side chain was more substantial when the 
trimethyl-lock was present, due to steric influences that localized electron density on the quinone 
ring.  The general trends and electrochemical phenomena observed for the Q-COOHs 
approximated the effect of quinone substitution on the electronics of the Q-DOPE lipids.  The 
information learned from these CV studies also allowed careful selection of a choice few 
substituted Q-COOHs for enzyme kinetics studies with NQO1 by another colleague in our 
research group.  To supplement the CV findings, X-ray crystallographic analysis of all 
crystalline Q-COOHs was conducted to investigate any structural variables (i.e. quinone 
substituents and trimethyl-lock) that could be affecting the electrochemical results.  Trialkyl-
locked quinones are well-known in the literature to be conformationally constrained, causing 
non-planarity in regions of the quinone ring nearest to the lock.1  The X-ray results, in fact, 
revealed a highly distorted quinone ring proximal to the trimethyl-locked propionic acid side 
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chain.  Conversely, the region of the quinone ring furthest from the lock retained a planar 
configuration.  From the X-ray data, it was also apparent that the substituent in the 2-position 
does not sterically affect the conformation, particularly the nearby carbonyl or the propionic acid 
side chain.   
 After learning about the electronics, structure, and enzyme kinetics of these substituted 
Q-COOHs, a family of 4 different Q-DOPE lipids were synthesized: QBr–, QH–, QMe–, and 
QnPrNH–DOPE.  These lipids were then prepared into liposomes according to the “lipid thin-film 
and extrusion” method and loaded with calcein (a fluorescent dye) to investigate the 
encapsulation and triggered release behavior of the 4 different Q-DOPE liposomes using 
fluorescence spectrometry.  The fluorescence data was analyzed in terms of two parameters: (1) 
lag time, which is the time it takes for the liposomes to reach minimum contraction after 
reduction, and (2) t50%, which is the time it takes for the liposomes to release half of their 
payload.  From fastest to slowest, the approximate average lag time of each liposome is as 
follows: QBr–DOPE (13 min.), QnPrNH–DOPE (20 min.), QMe–DOPE (25 min.), and QH–DOPE 
(40 min.).  The relative order is the same for t50%, and the approximate average t50% values are: 
QBr–DOPE (23 min.), QnPrNH–DOPE (33 min.), QMe–DOPE (37 min.), and QH–DOPE (81 min.).  
It is clear from the calcein release profiles that the nature of the quinone triggers (i.e. quinone 
substitution) does affect the stimuli-responsive behavior of the liposomes and can therefore be 
controlled by incorporating various functionalities onto the quinone ring.  The average sizes and 
zeta potentials of these Q-DOPE liposomes (no encapsulated calcein) were also measured using 
dynamic light scattering (DLS) to better characterize these liposomes and possibly help explain 
the fluorescence results.  It was found that all the liposomes had an average diameter of 
approximately 100 nm, with the exception of QBr–DOPE that had a slightly larger average 
diameter of 131 nm.  The average zeta potentials for the liposomes are all about the same: 
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QnPrNH–DOPE (−55 mV), QBr–DOPE (−58 mV), QH–DOPE (−58 mV), and QMe–DOPE  
(−60 mV).  Even though the QnPrNH–DOPE liposomes did have the most positive zeta potential, 
the impact of the n-propylamino group (possibly protonated) did not have a considerable impact 
on the overall charge of the bilayer. 
5.2 Conclusions 
 The results presented in this dissertation demonstrate the ability to exercise control over 
the stimuli-responsive behavior of redox-active, Q-DOPE liposome delivery agents by 
incorporating various functionalities onto the quinone ring.  The capacity to achieve molecular-
level manipulation of a nanosized delivery system is exceedingly important to a variety of 
analytical and medical applications, but is the cornerstone of present and developing drug 
delivery technologies.  The electrochemical properties of a series of water-soluble Q-COOHs 
(Q-DOPE precursors) in aqueous media were successfully characterized by CV and showed that 
quinone substitution significantly affects the electronics of the overall molecule.  This 
observation was realized in the fluorescence experiments, where the 4 different Q-DOPE 
liposomes exhibited various destabilization behaviors and rates of calcein release.  The synthetic 
routes to the target Q-DOPE lipids share a common pathway: once the quinone trigger moieties 
are synthesized as Q-COOH intermediates, their coupling to the DOPE lipid is achieved in two 
subsequent steps using established protocols.  Because of this convergent-type synthetic strategy, 
and the fact that the trigger group is always a quinone, these Q-DOPE liposomes can easily be 
modified to generate the desired stimuli-responsive behavior for any given application.   
5.3 Outlook 
 With increasing knowledge of the tumor microenvironment and cancer cell biology, the 
future of drug delivery seems to be evolving toward the development of “multifunctional 
nanocarriers” that are able to recognize tumor sites and utilize differentiating characteristics of 
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these diseased sites to selectively release their therapeutic payload, thus maximizing drug 
efficacy and limiting systemic exposure to healthy tissues.2  While the toxicity of the nanocarrier, 
itself, is a concern because of poorly-defined biological properties of nanostructures,3 no 
significant in vivo toxic effects have been reported for nanocarriers, with the exception of those 
that are cationic.4   
 In comparison to other leading nanocarriers, liposomes offer an all-inclusive approach to 
drug delivery due to their versatility that comes from a variety of functional handles (e.g. 
synthetic modification of lipids, blending multiple lipids together, incorporation of targeting 
ligands, cholesterol, non-immunogenic agents, to name a few).5  The redox-active, Q-DOPE 
drug delivery system described herein provides an additional degree of control over its 
stimuli-responsive behavior through substitution of different functional groups on Q – a task that 
does not require complete synthetic overhaul or new routes.  In fact, the molecular make-up of 
the liposomes remains virtually constant with these slight modifications, maintaining the 
Q-DOPE framework, which is advantageous from both synthetic and pharmacological 
point-of-views.   
 According to a publication in the Journal of the National Cancer Institute, combination 
chemotherapy should be the focus of future delivery systems so that multiple drugs are 
distributed within tumors site-specifically and in a timely manner.6  Moreover, it is known that 
some antitumor drugs are more effective when released at intermediate rates, compared to faster 
or slower rates, such as vincristine that is cell-cycle specific.7-8  Therefore, our redox-active 
liposomes could be envisioned as a “dual time-release” type system.  For example, QH-DOPE 
liposomes could encapsulate a drug to be released slowly over time, while QMe-DOPE liposomes 
are loaded with a different drug to be released more quickly; administered together, these two 
types of liposomes could achieve custom, time-release delivery of two different 
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chemotherapeutic drugs.  Similarly, two (or more) different Q-DOPE lipids could be blended 
into the same liposomal formulation to alter the release rates and/or behaviors in order to achieve 
optimum temporal delivery. 
   This whole concept of being able to control the rate of drug release through molecular 
modification of the carrier is not a new idea and has been exemplified in previous  
prodrug formulations, such as that of Greenwald et al.9  The pharmacokinetics of these 
PEG-daunorubicin prodrug conjugates can be controlled and adjusted by careful selection of the 
spacer group, trigger/linker bond, and degree of shrubbery (steric bulk) on the aromatic ring.9-10  
Likewise, our redox-active Q-DOPE lipids possess several adjustable (molecular-based) facets, 
in addition to Q-substitution, with which to modify the stimuli-responsive behavior of the 
liposomes: length of the geminal dialkyl chains, size of the lactone ring, added elimination 
products (i.e. reducing agent), and the molecular destabilization mechanism (i.e. cleavable 
groups vs. lactonization).     
 In their 2005 review, Jung and Piizzi demarcate the gem-disubstituent effect in the 
formation of small-, medium-, and large-sized rings that result from intramolecular 
cyclizations.10  Even though the origin of the gem-disubstituent effect is different depending on 
ring size (i.e. Thorpe-Ingold for smaller rings; conformational restriction/relief of ground-state 
steric strain for medium-sized and larger rings), the rate of cyclization is enhanced by the 
presence of longer and/or bulkier alkyl chains due to nonbonded interactions.10  For example, 
Brown et al. found that the rate of intramolecular cyclization of a series of 4-bromobutylamines 
(to their pyrrolidines) significantly increased as the size/bulk of gem-dialkyl chain increased: 
cyclization of the gem-dimethyl compound (4-bromo-2,2-dimethylbutylamine) occurred at a 
relative rate (krel) of 158, while the relative cyclization rate of the gem-diisopropyl compound  
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